THE MILAN GERIATRICS 75+ COHORT STUDY: UNRAVELLING THE DETERMINANTS OF HEALTHY AGEING AND LONGEVITY by G. Ogliari
  
The Milan Geriatrics 75+ Cohort Study: 
unravelling the determinants of healthy ageing and longevity 
 
 
 
Giulia Ogliari 
 
Facoltà di Medicina e Chirurgia 
Dipartimento di Scienze Cliniche e di Comunità 
Anno Accademico 2015-2016 
Ciclo XXVIII 
Settore MED/09 – Medicina Interna 
Dottorato conseguito in Scienze fisiopatologiche, neuropsicobiologiche e assistenziali del 
ciclo della vita 
Relatori: Prof.ssa Daniela Mari, Università degli Studi di Milano e Prof. Rudi G.J. 
Westendorp, Universiteit Leiden 
 
  
  
 
 
 
 
 
 
 
 
 
To my family, 
Professor Carlo Vergani, 
Roelof 
  
  
The Milan Geriatrics 75+ Cohort Study: 
unravelling the determinants of healthy ageing and longevity 
Giulia Ogliari 
 
Thesis chapters 
1. Introduction 
2. Blood pressure and cognition 
3. Blood pressure and mortality 
4. Thyroid status and mortality 
5. Heart rate, heart rate variability and functional decline 
6. Blood pressure variability and functional decline 
7. General discussion 
8. Summary in English 
9. Summary in Italian 
10. Summary in Dutch 
List of publications 
Curriculum vitae 
Acknowledgements 
  
  
 
 
 
 
 
 
 
 
 
Chapter 1 
Introduction 
 
 
 
 
 
 
  
  
Introduction 
An ageing Europe, an ageing Italy 
Europe’s population is rapidly ageing1,2. Adults aged 75 years and over now account for 8.3% 
of the European population, a proportion which is expected to increase up to 10.7% by 20302. 
In parallel, the birth rate is decreasing2. As a result, the population age structure will 
dramatically change. The proportion of older adults in non-working age will increase compared 
to that of adults in working age2. In the future, older adults may lack social support from 
younger generations. Therefore, it will be crucial to preserve functional independence in old 
age. 
This demographic transition is already evident in Italy. The population proportion over 75 years 
is now 10.7% of the total (6.6 million out of 62 million inhabitants)2. Italy’s life expectancy at 
birth is now 79.5 years for men and 84.9 years for women, among the highest in the world3. 
Such structural changes in the population represents a big challenge for both society and 
medicine4. With ageing, the burden of age-related diseases, disability and functional 
dependency increases5. Among age-related diseases, cardiovascular diseases and dementia are 
prominent5-7. Their prevalence dramatically increases with advancing age5-9. Both 
cardiovascular diseases and dementia are leading causes of disability and mortality5. 
It can be postulated that age-related diseases lead to a loss of function of different physiological 
systems and therefore to a state of frailty, an increased vulnerability to stressors, which 
eventually results in functional decline or death10-13. Conversely, mechanisms that preserve the 
homeostasis of different physiological systems may favor resilience to stressors, and eventually 
delay functional decline or death. 
The homeostasis of the cardiovascular system is crucial for preserving cognitive and functional 
status14-17. 
However, the mechanisms behind homeostasis may change with ageing. With ageing, changes 
in different physiological parameters may occur.  The optimal values of these parameters as 
well as the threshold of disease may shift with age.  Blood pressure and thyroid status may be 
among these parameters. Older adults may benefit from different set-point of homeostasis, 
  
compared to younger adults. A deeper insight in the homeostasis of older adults is necessary 
to tailor interventions aimed at delaying functional decline and mortality in old age. 
The aim of this thesis is to explore the homeostasis of older adults, with emphasis on the 
cardiovascular system. This thesis will examine the associations of cardiovascular parameters 
(blood pressure and its variability, heart rate, heart rate variability) and thyroid status with 
clinically relevant outcomes (functional and cognitive status, mortality).  
 
Blood pressure: shifting the cut-off values 
With ageing, systolic blood pressure increases, while diastolic blood pressure increases until 
the age of 60 years and then gradually decreases18. Optimal blood pressure targets in old age 
are still controversial, as reflected by divergent recommendations in different international 
guidelines19-23. In middle-age, higher blood pressure is strongly and consistently associated 
with adverse health outcomes, including increased risk for dementia and mortality24. However, 
these associations attenuate or even reverse with ageing24. Findings from population-based 
studies have suggested that these associations may be modified by chronological and biological 
age25-30. Indeed, lower blood pressure may be associated with increased mortality risk in the 
oldest and in the frailest adults25-30. In contrast, findings from trials indicate that 
antihypertensive treatment effect may not vary according to frailty31. For instance, the 
Hypertension in the Very Elderly Trial (HYVET) showed no difference in antihypertensive 
treatment benefit between the frailer and the fitter participants31. However, HYVET excluded 
older adults with dementia, thus potentially limiting the generalizability of its findings31. 
 
Thyroid status: shifting the cut-off values 
Thyrotropin (TSH), free thyroxine (fT4) and free triiodotironine (fT3) have profound effects 
on the ageing process, which may vary according to sex and age32-34. Optimal thyroid status in 
old age is an area of controversy33,34. The distribution of TSH progressively shifts towards 
higher values with ageing35,36. This shift may arise from a higher prevalence of occult thyroid 
disease or from selective survival of individuals with a constitutively lower thyroid status37,38. 
  
Therefore, it is debated whether the upper reference limit for TSH should be age- and sex-
specific33,34. 
 
Heart rate, heart rate variability 
Heart rate variability is the physiological variation in the beat-to-beat time interval39. By 
modulating heart rate and heart rate variability, the autonomic nervous system keeps blood 
pressure constant within a certain range, so to maintain adequate perfusion to vital organs. In 
particular, higher heart rate variability is a homeostatic mechanism to buffer detrimental 
variations in blood pressure in response to stressors40,41. 
 
Blood pressure variability 
Visit-to-visit blood pressure variability is the intra-individual variation in blood pressure 
measures over different clinic visits42. Higher blood pressure variability, independent of mean 
blood pressure, has been associated with clinical and subclinical vascular organ damage42. 
Higher blood pressure variability may reflect impaired homeostasis, in particular impaired 
baroreflex function, in the context of central autonomic dysregulation43.  Furthermore, it may 
cause oscillations in perfusion of vital organs, including the brain, the heart and the kidney, 
thus leading to damage of these organs.  
 
The Milan Geriatrics 75+ Cohort Study 
Current evidence for the treatment of older adults comes from population-based cohort studies 
and randomized clinical trials. However, this evidence may not be easily extrapolated to patient 
populations, whom clinicians encounter in everyday clinical practice (Figure 1). Clinical trials 
tend to selectively recruit fit older adults with few comorbidities. The HYVET trial aimed at 
solving the controversies on antihypertensive treatment in the very old individuals, by 
specifically enrolling adults aged 80 years or over44. However, a recent population based study 
showed that only one out of ten older adults would have been eligible for inclusion in 
HYVET45. Despite HYVET’s focussed aim and large sample, the benefits and harms of 
  
antihypertensive treatment in frailer old adults remain a controversial topic. Population-based 
studies may enrol older adults with a broader spectrum of impairment and co-morbidities. 
However, also population-based studies may be affected by a response bias, as particularly frail 
older adults tend to refuse participation in these studies46. The generalizability of data from 
trials and population-based studies to patients’ populations is debatable. Clinicians are 
confronted with lack of data in patients’ populations, in which comorbidities, functional and 
cognitive impairment may be more prevalent and severe, and their interplay within homeostasis 
more complex. 
 
 
Figure 1. Bridging the gap. Current evidence is derived from population-based cohort studies and randomized 
controlled trials. Both types of studies may be biased by failing to include frail individuals, due to either lower 
response rate in the frailer or exclusion criteria.  Data are lacking on older outpatients, a potentially diverse 
population, thus the need for an outpatients cohort study. 
 
To bridge the gap between current evidence and clinical practice needs, we designed the Milan 
Geriatrics 75+ Cohort Study, a prospective hospital-based outpatient cohort study (Figure 1). 
This study included 1861 men and women aged 75 years and older who were consecutively 
referred for a first comprehensive geriatric visit to the Geriatric Unit of the IRCCS Ca’ Granda, 
Milan, Italy, in the period between January 3, 2000 and March 25, 2004. These participants 
routinely underwent an extensive standardized structured medical examination and 
comprehensive geriatric assessment. As the Italian health care system guarantees universal 
  
coverage, the Milan Geriatrics 75+ Cohort Study represents the population seeking geriatric 
care with no restriction based on socio-economic status47. 
The Milan Geriatrics 75+ Cohort Study enrolled mainly women (about two thirds of 
participants). This may have resulted from higher life expectancy, higher prevalence of 
comorbidities such as dementia, and higher health care utilization in women compared to 
men48,49. This significant proportion of women allowed us to explore sex-differences in the 
association between thyroid status and mortality. 
 
The PROSPER Study 
The PROspective Study of Pravastatin in the Elderly at Risk (PROSPER) was a randomised, 
double blind, placebo controlled trial designed to investigate the effect of pravastatin in the 
prevention of vascular events50,51. The PROSPER cohort included older adults aged 70-82 
years with pre-existing, or risk factors for, cardiovascular disease, from three collaborating 
centres in Ireland, Scotland, and the Netherlands. Approximately half of the participants had a 
diagnosis of cardiovascular disease, defined as myocardial infarction or stable angina, 
intermittent claudication, stroke or transient ischaemic attack, or previous vascular surgery. 
The rest of the participants had one or more major cardiovascular risk factors, defined as 
hypertension, cigarette smoking, or diabetes mellitus. The PROSPER participants had high 
functional and cognitive status at baseline. Therefore, the PROSPER cohort allowed us to 
explore the associations between cardiovascular risk factors (heart rate, heart rate variability 
and blood pressure variability) and functional decline in a cohort with high baseline functional 
status and at high risk for cardiovascular disease. 
 
  
  
Outline of this thesis 
Chapter 2, 3 and 4 report findings from the Milan Geriatrics 75+ Cohort Study. 
Chapter 2 explores the association between blood pressure and cognition, and whether it varies 
according to age and functional status. 
Chapter 3 examines the relationship between blood pressure and mortality risk, and whether 
it varies according to functional and cognitive status. 
Chapter 4 investigates the association between thyroid status and mortality risk in euthyroid 
older adults, and whether it differs by sex and age. 
Chapter 5 and 6 report findings from the PROSPER cohort. 
Chapter 5 presents new evidence on the association of heart rate and heart rate variability with 
functional decline in older adults at high risk of cardiovascular disease. 
Chapter 6 analyses the relationship between blood pressure variability and functional decline 
in older adults at high risk of cardiovascular disease. 
Chapter 7 summarises and discusses the main findings of this thesis. 
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Chapter 2 
Blood pressure and cognition 
 
 
 
 
 
Manuscript based on this chapter has been published as: 
Ogliari G, Sabayan B, Mari D, Rossi PD, Lucchi TA, de Craen AJ, Westendorp RG. Age- and 
Functional Status-Dependent Association Between Blood Pressure and Cognition: The Milan 
Geriatrics 75+ Cohort Study. J Am Geriatr Soc. 2015;63(9):1741-8. 
 
  
  
ABSTRACT 
Objectives: To evaluate whether the relationship between blood pressure (BP) measures and 
cognitive function is different according to age and functional status in older outpatients. 
Design: Cross-sectional. 
Setting: Outpatient hospital-based Milan Geriatrics 75+ Cohort Study. 
Participants: Individuals aged 75 and older (N = 1,540). 
Measurements: Blood pressure, Mini-Mental State Examination (MMSE), basic activities of 
daily living (ADLs), and instrumental activities of daily living (IADLs) were assessed. 
Associations between BP measures and MMSE score were first analyzed in the total population 
using linear regression models and were then further examined according to strata of age, 
ADLs, and IADLs. All analyses were adjusted for sociodemographic factors and presence of 
comorbidities. 
Results: In the total population, higher systolic BP (SBP), diastolic BP (DBP), pulse pressure 
(PP), and mean arterial pressure (MAP) were all associated with higher MMSE score (all P < 
.05). Each 10-mmHg higher SBP and DBP was associated with a 0.26- and 0.55-point higher 
MMSE score, respectively. The associations between MMSE score and SBP, DBP, and MAP 
differed materially according to strata of age and functioning and were most pronounced in 
those aged 85 and older, with ADL impairments, and with IADL impairments. 
Conclusion: Higher BP is associated with better cognitive function in the oldest old and in 
those with impaired functional status. 
  
  
INTRODUCTION 
Controversy persists on the relationship between blood pressure (BP) and cognitive function 
in old age1. Midlife hypertension has been consistently associated with an increased risk for 
cognitive impairment and dementia in later life2-5. On the contrary, data regarding the 
association between BP and cognition in older adults are conflicting. Some population-based 
observational studies have shown an inverse association between higher BP and cognitive 
function6, whereas others have shown a direct association7–9 or no association10. Whether this 
heterogeneity reflects differences in age11 and level of frailty12 of the participants is debated. It 
has been suggested that higher BP may be needed to maintain brain perfusion in biologically 
older individuals with widespread atherosclerotic vascular damage13. 
Most of the evidence in the literature is for older adults in population-based studies. Less is 
known about older adults who require outpatient medical assistance. The generalizability of 
data from population-based studies to clinical practice is questionable. Older outpatients may 
be frailer than older adults in the general population. In everyday clinical practice, healthcare 
professionals are confronted with these outpatients’ needs. It is of critical importance to 
investigate this potentially diverse population. Therefore, the current authors investigated the 
relationship between BP and cognitive function in the Milan Geriatrics 75+ Cohort Study, an 
outpatient hospital-based cohort study. The objective was to assess whether higher BP is 
associated with better cognitive function in geriatric outpatients over a wide range of age and 
functional dependency. 
 
METHODS 
Study Design and Participants 
The Milan Geriatrics 75+ Cohort Study is an outpatient hospital-based prospective cohort study 
of outpatients of the Geriatric Unit of the IRCCS Ca’ Granda Foundation Maggiore Policlinico 
Hospital, Milan, Italy. Between January 3, 2000, and March 25, 2004, 3,608 new consecutive 
outpatients visited the Geriatric Unit. They routinely underwent an extensive standardized 
structured medical examination and comprehensive geriatric assessment. With the informed 
consent of these individuals, data were collected in structured paper records that were 
consecutively numbered and stored in the Geriatric Archive; 3,499 (97.0%) paper records were 
  
retrieved. Of these, 2,267 were for people aged 75 and older at the time of the first visit. 
Seventy-four individuals had no comprehensive geriatric assessment, and 332 had neither a 
Mini-Mental State Examination14 (MMSE) nor an activities of daily living15 (ADLs) score; 
these individuals were excluded from the final cohort. Therefore, the Milan Geriatrics 75+ 
Cohort Study includes 1,861 patients aged 75 and older. The current study included 1,540 
individuals for whom BP and cognitive evaluation were available. The medical ethical 
committee of IRCCS Ca’ Granda approved the study. 
 
Comprehensive Geriatric Assessment 
Outpatients accessed the Geriatric Unit only through the referral for a geriatric visit by a 
physician (their general practitioner in the majority of cases). The reason for first visit was 
recorded. Outpatients were required to bring all current medications and all medical documents 
including letters of discharge from acute-care hospitals, rehabilitation centers or emergency 
departments, drug prescriptions, reports of visits with other physicians, and reports of the 
Italian Commissions for the Ascertainment of Civil Disability to their first visit, which was 
with a trained physician and lasted 2 hours. Physicians collected demographic data, 
physiological anamnesis, past and present medical history, and current medication use in paper 
records through structured multiple-choice lists of demographic variables and comorbidities. 
Physicians also performed a basic neurological examination, took anthropometric 
measurements, and evaluated functional and cognitive status. Laboratory tests were ordered if 
recent ones were not available, and the results were recorded. Physicians registered chronic, 
cyclical, and as-needed drugs, including prescription and over-the-counter medications. 
Antihypertensive drugs were defined according to Anatomical Therapeutic Chemical (ATC) 
classification codes C02, C03, C07, C08, and C0916. Close relatives frequently accompanied 
participants to the first visit and acted as informants for the validation of data on functional 
status and drug assumption. 
 
Blood Pressure 
Arterial BP was measured during the first visit using a mercury sphygmomanometer at heart 
level, with an adjustable cuff, in the seated position, after at least 5 minutes of rest and no 
  
vigorous exercise in the preceding 30 minutes. A special cuff was available for obese subjects. 
Systolic BP (SBP) and diastolic BP (DBP) were manually auscultated. Pulse pressure (PP) was 
calculated as SBP minus DBP and mean arterial pressure (MAP) as 1/3SBP + 2/3DBP. 
 
Cognitive and Functional Status 
Cognitive function was assessed using the 30-item Mini-Mental State Examination (MMSE)14. 
Functional status was assessed using the Katz ADLs15 and Lawton IADLs17 questionnaires. 
ADLs included six items (rising or lying down, feeding, dressing, bathing, toileting, urinary 
and fecal continence), and IADLs included eight items (using a telephone, shopping, doing 
housework, doing laundry, preparing meals, using transportation, taking medications, 
managing money). ADL scores range from 0 to 6 and IADL scores from 0 to 8, with 0 
indicating total dependence and the maximum score total independence. Information on 
functional status was checked with close informants. 
 
Comorbidities and Lifestyle Factors 
Hypertension was defined as diagnosis of hypertension or treatment with antihypertensive 
drugs. Coronary heart disease was defined according to a history of acute myocardial infarction 
or angina pectoris or therapy with nitrates. History of transient ischemic attack or stroke, 
diabetes mellitus, atrial fibrillation, claudication, and Parkinson’s disease was confirmed using 
medical documents. Diagnosis of probable Alzheimer’s disease was based on international 
criteria18,19. Dementia with Lewy bodies, frontotemporal dementia, and primary progressive 
aphasia were classified as other neurodegenerative conditions. Alcohol abuse was defined as 
intake of 70 g of alcohol per day or more. Cancer was defined according to a diagnosis within 
the previous 5 years. Glomerular filtration rate (GFR), which is an index of renal function, was 
calculated using the Modification of Diet in Renal Disease Study Group formula20. Symptoms 
of anxiety and depression were self-reported or stated in medical documents. Smoking was 
dichotomized as never or ever (current or previous). Education was defined as years of school 
attended. 
 
  
Medications 
Number of medications was defined as the number of drugs taken chronically or cyclically. 
Antihypertensive drugs were defined as ATC classification codes C02 (antiadrenergics), C03 
(diuretics), C07 (beta-blockers), C08 (calcium-channel blockers), and C09 (agents acting on 
the renin-angiotensin system)16. Psychotropic drugs were defined as ATC classification codes 
N05A (antipsychotics), N05B (anxiolytics), N05C (sleep-inducers or sedatives), and N06A 
(antidepressants). 
 
Statistical Analysis 
In summary statistics, categorical variables were reported as percentages and continuous 
variables as medians and interquartile ranges (IQRs) when skewed. Linear regression models 
were used to analyze associations between variables of interest. Analyses were performed in 
four steps. Model 1 presents unadjusted MMSE mean scores. In Model 2, a minimally adjusted 
model, analyses were adjusted for age, sex, and education. In Model 3, analyses were adjusted 
for relevant comorbidities and medication use; each variable was entered in the model 
separately. In Model 4, a fully adjusted model, analyses were further adjusted for renal 
function. The relationship between BP measures (predictors) and MMSE score (dependent 
variable) was examined in total population and within age, ADL, IADL, and BP control strata. 
Three age strata were defined (75–79, 80–84, ≥85). The total population was divided into two 
ADL strata (preserved ADL function (ADL score = 6); impaired ADL function (ADL score < 
6)) and two IADL strata (IADL score < 5 (median); IADL score ≥5). Subjects were classified 
into three groups of BP control: normotension (no history of hypertension, SBP < 140 mmHg, 
DBP < 90 mmHg), controlled hypertension (history of hypertension, SBP < 140 mmHg, DBP 
< 90 mmHg), and uncontrolled hypertension (history of hypertension, SBP ≥ 140 mmHg, DBP
≥ 90 mmHg). Interaction between BP measures and age, ADLs, and IADLs in relation to 
cognition was assessed. Interaction terms were calculated by multiplying BP measures by age 
and ADL and IADL scores, using age and ADL and IADL scores as continuous variables. 
Sensitivity analyses were performed after exclusion of SBP and DBP outliers; outliers were 
subjects with SBP or DBP measurements 2 standard deviations or more below or above the 
  
mean of the total population. All analyses were performed using SPSS version 20.0.0 (SPSS, 
Inc., Chicago, IL). 
 
RESULTS 
Table 1 summarizes the characteristics of participants at first visit according to tertile of SBP. 
The median age of the study population was 82 (range 75–101), and 70% were female. Median 
SBP was 145 mmHg, and median DBP was 80 mmHg. Participants with higher SBP were more 
likely to be female and had a higher prevalence of hypertension and antihypertensive use. 
Participants with higher SBP were more likely to use alpha-antiadrenergics and angiotensin-
converting enzyme inhibitors or angiotensin II antagonists; participants with lower SBP used 
antipsychotics more frequently. Participants in the lowest tertile of SBP had the highest 
prevalence of Parkinson’s disease (all P < .05). 
Table 2 shows the association between BP measures and cognitive function in the total 
population. Higher SBP, DBP, PP, and MAP were associated with higher MMSE score in all 
models of adjustment (all P < .05). In the fully adjusted model, a 10-mmHg increase in SBP 
was associated with a 0.26-point higher MMSE score (95% confidence interval (CI) = 0.13–
0.40), a 10-mmHg increase in PP with a 0.20-point higher MMSE score (95% CI = 0.03–0.37), 
a 10-mmHg increase in DBP with a 0.55-point higher MMSE score (95% CI = 0.27–0.83), and 
a 10-mmHg increase in MAP with a 0.50-point higher MMSE score (95% CI = 0.27–0.74). In 
the fully adjusted model, subjects in the lowest SBP tertile (SBP <140 mmHg) had the lowest 
MMSE score; subjects in the lowest and middle DBP tertiles (DBP <90 mmHg) had lower 
MMSE scores than those in the highest DBP tertile. 
Table 3 presents the age-stratified analyses of the association between BP measures and 
cognitive function. Age significantly modified the association between MMSE score and SBP, 
DBP, and MAP (all P-values for interaction < .05 except in Model 4 for SBP (P = .15) and 
MAP (P = .05)). The interaction between age and PP was not significant. In all adjusted models, 
the association between higher SBP, DBP, and MAP and MMSE score was most pronounced 
in participants aged 85 and older. 
The modifying effect of functional status (ADL and IADL scores) on the relationship between 
BP measures and MMSE score is shown in Figure 1. In the unadjusted model, all P-values for 
  
interaction between all BP measures and ADL/IADL score were less than .05 (Figure 1). In the 
fully adjusted model, P-values for interaction between SBP, DBP, and MAP and ADL score 
were less than .10; all P-values for interaction between all BP measures and IADL score were 
less than .05. In all models, higher BP measures were associated with higher MMSE score in 
subjects with at least partial dependence in ADLs (ADL score < 6) but not in subjects with full 
independence (ADL score = 6). Similarly, higher BP was related to better cognitive function 
in subjects with worse IADL performance (IADL score < 5). Conversely, no association was 
observed in those with better IADL score (IADL score ≥ 5). Estimates of mean MMSE scores 
in Figure 1 are derived from the unadjusted model; results were similar in the fully adjusted 
model (data not shown). 
No difference in MMSE scores was observed in the fully adjusted model between participants 
with normotension and those with controlled hypertension, between participants with 
normotension and those with uncontrolled hypertension, or between participants with 
controlled hypertension and those with uncontrolled hypertension (data not shown). 
In sensitivity analyses after exclusion of BP outliers (n = 105), higher SBP, DBP, PP, and MAP 
remained associated with higher MMSE score in the total population and in subjects with 
impaired ADL or IADL status, even after full adjustment (all P < .05, data not shown). 
 
DISCUSSION 
Higher BP measures were associated with better cognitive function in outpatients aged 75 and 
older and particularly in those aged 85 and older. The association was significantly stronger in 
those with impaired functional status, as measured by internationally validated ADL and IADL 
scale scores. 
Both age and functional status modified the relationship between BP and cognitive function. 
The correlation between SBP, DBP, and MAP and MMSE score becomes more pronounced 
with increasing age. In those aged 85 and older, higher BP measures were consistently 
associated with higher MMSE scores. Likewise, the positive association between BP measures 
and cognitive function was detected in participants with worse functional impairment, although 
this association was absent in those with better preserved functional status. 
  
The results of this study are consistent with those of earlier reports showing that lower BP was 
associated with worse cognitive performance in the oldest adults7 and in centenarians8. The 
age-dependent relationship between BP and cognitive function has been previously 
hypothesized1. The modifying effect of functional status is a novel finding. In the population-
based Leiden 85-plus Study, higher SBP and PP were associated with lower annual decline in 
MMSE score in the oldest adults with greater physical disability, although interactions were 
not significant7. All of these studies have used population samples. The current study showed 
that the positive association between high BP and good cognitive performance in frail older 
adults can be extrapolated to the outpatient clinic. 
These findings may have different biological explanations. First, cognitive impairment itself 
lowers BP. The central nervous system is involved in BP regulation; brain atrophy and 
Alzheimer-type lesions in the prefrontal areas involved in central BP regulation may cause a 
decline in BP21. Alternatively, low BP and cognitive impairment share common risk factors 
such as decreasing cardiac function. However, in the current study, the associations between 
BP measures and cognitive performance remained significant after adjustment for risk factors 
and comorbidities that affect cardiac function. Finally, low BP may increase the risk of worse 
cognitive function. Episodic or sustained hypotension, and possibly excessive treatment of 
hypertension, may induce brain hypoperfusion, leading to ischemia and hypoxia, which may 
enhance the development of neurodegenerative processes22. Longitudinal studies have showed 
that declining BP over time correlates with incident dementia and with imaging and biological 
markers of neurodegenerative processes. The Kungsholmen Project reported that BP markedly 
decreased 3 years before a dementia diagnosis and continued to decline thereafter23. In the 
Rotterdam Scan Study, elderly adults without dementia with a decline of more than 10 mmHg 
in DBP had more cortical atrophy than subjects with stable BP over a 20-year period.24 
Longitudinal decrease in MAP was found to be associated with an increase in p-tau181, a 
cerebrospinal fluid biomarker of Alzheimer’s disease, in subjects with hypertension25. 
Why should functional status affect the relationship between BP and cognition? Functional 
status may be seen as a reflection of the biological age of older adults. Of note, functional status 
has been shown to affect the association between BP and subsequent mortality risk. In the 
National Health and Nutrition Examination Survey, functional status was assessed as walking 
speed for a 20-foot distance in individuals aged 65 and older. High SBP (>140 mmHg) was 
associated with greater mortality in fast walkers, whereas the association was inversed in those 
  
who did not manage to complete the walking test26. Likewise, in the population-based 
Longitudinal Ageing Study Amsterdam, low DBP was associated with higher all-cause 
mortality risk in the oldest adults and in participants with a combination of physical and 
cognitive dysfunction, whereas BP was not related to mortality in more-vital older 
individuals27. Moreover, in the Leiden 85-plus Study, functional status modified the association 
between higher BP and risk of stroke in the oldest adults28. 
Functional impairment may be a consequence of hypertension, because most of the subjects 
with low BP late in life had higher BP earlier in life24. Functional impairment thus reflects the 
lifelong atherosclerotic burden of elderly adults. Atherosclerotic damage stiffens brain arteries 
and impairs brain perfusion regulation. Therefore, subjects with more atherosclerosis are more 
susceptible to episodic or sustained hypotension because they have a lower critical threshold 
for cerebral hypoperfusion22. In the Kungsholmen Project, the association between SBP decline 
and increased risk of dementia was observed only in people with baseline SBP less than 160 
mmHg or vascular disease. In subjects with vascular disease, there was a dose-response 
relationship between SBP decline and risk of dementia23. 
Disentangling the relationship between BP and cognition in frail older people has significant 
clinical implications. Given the increasing life expectancy of populations worldwide29, 
dementia is a leading cause of disability30. Therefore, a major public health challenge is 
prevention of dementia through management of its modifiable risk factors. BP is a major target, 
but optimal BP goals are unclear in individuals aged 80 and older31 and in frail elderly adults32. 
The Systolic Blood Pressure Intervention Trial (SPRINT), which aims to assess whether 
individuals aged 75 and older differ from younger individuals in their response to hypertension 
treatment, specifically addresses this. Moreover, the nested substudy, SPRINT Memory and 
cognition IN Decreased hypertension (SPRINT-MIND), is designed to evaluate the effect of 
treatment on age-related decline in cognition and incidence of all-cause dementia33. 
The few previous clinical trials on the prevention of dementia with antihypertensive treatment 
have provided conflicting results, partly because of short follow-up and the heterogeneity of 
antihypertensive drugs. The Systolic Hypertension in the Elderly Program34 and the Medical 
Research Council35 trials failed to show any difference in effect on cognition between placebo 
and active treatment with diuretics or beta-blockers as first-line antihypertensive agents. In 
contrast, the Systolic Hypertension in Europe36 showed that antihypertensive therapy starting 
  
with the dihydropyridine calcium channel blocker nitrendipine reduced the incidence of 
dementia by 55% over a median follow-up of 3.9 years. In the Perindopril Protection Against 
Recurrent Stroke Study trial37, combined treatment with perindopril and indapamide reduced 
stroke-related dementia by 50%. The Hypertension in the Very Elderly Trial (HYVET)38 failed 
to show a significant reduction in the incidence of dementia with treatment with indapamide 
and perindopril. The HYVET data, when combined in a meta-analysis with other placebo-
controlled trials of antihypertensive treatment, provided evidence that antihypertensive 
treatment is beneficial for reducing incidence of dementia in fit elderly adults. Nevertheless, a 
major weakness of these trials is the inclusion of relatively healthy subjects, which limits the 
generalizability of results to other populations. A recent community-based study found that 
only 9% of the oldest adults with hypertension were eligible for inclusion in HYVET.39 As 
further proof of the selective recruitment of fit elderly adults, the incidence of dementia in the 
placebo group of the trials was lower than in population-based studies36,40. Evidence of the 
generalizability of the results of clinical trials to the population of elderly outpatients is even 
more limited. 
A strength of this study is that it investigated the connection between BP and cognition in an 
unselected population of elderly outpatients. To the knowledge of the authors, this is the largest 
study to be performed in a general geriatric unit. Another strength is that it proves the utility of 
categorizing elderly adults on the basis not only of chronological age, but also of markers of 
biological age as ADL and IADL scores. Any trained physician can collect this information. 
The main limitation of this study is the cross-sectional observational design, which prevents 
causality relationships from being inferred. Second, the MMSE, a widely used global measure 
of cognitive function, might have missed variation in executive function, the domain of 
cognition that hypertension particularly affects. Third, a single BP measurement was used in 
the analyses. Because BP is highly variable in older adults, participants may have been 
misclassified, although is it likely that misclassification would have occurred randomly, 
possibly leading to underestimation of true associations. Nevertheless, the data add further 
evidence of low BP as a risk factor for frail older adults in an outpatient setting. 
In conclusion, higher BP is associated with better cognitive function in older individuals aged 
over 85 and in those with impaired functional status. The optimal threshold of BP may depend 
on both chronological and biological age (reflected by functional status). Therefore, BP 
management in older adults should be personalized, taking into account functional status.
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Table 1. Characteristics of study population according to tertile of systolic blood pressure 
(starts) 
Characteristic Total 
population 
Systolic blood pressure tertile p-value 
 n = 1,540 Low 
n=431 
Middle 
n=601 
High 
n=508 
 
Demographic      
  Age, years median [IQR] 82 [78, 86] 81 [78, 87] 81 [78, 85.5] 82 [79, 86] 0.222 
  Females, n (%) 1,075 (69.8) 288 (66.8) 404 (67.2) 383 (75.4) 0.004 
  Education, years, median [IQR] 6 [5, 12] 7 [5, 12] 6 [5, 11] 6 [5, 11] 0.615 
Blood pressure (mmHg)      
  Systolic, median [IQR] 145 [130, 160] 130 [120, 130] 140 [140, 150] 170 [160, 175] <0.001 
  Diastolic, median [IQR] 80 [80, 90] 80 [70, 80] 80 [80, 90] 90 [80, 95] <0.001 
  Pulse, median [IQR] 60 [50, 70] 50 [40, 55] 60 [60, 70] 80 [70, 90] <0.001 
  Mean arterial, median [IQR] 103 [97, 110] 93 [87, 97] 103 [100, 107] 113 [110, 120] <0.001 
Cognitive and functional status      
  MMSE, median [IQR] 26 [20, 28] 25 [17, 28] 25 [21, 29] 26 [21, 29] 0.003 
  ADL, median [IQR] 5.5 [4, 6] 5 [3.5, 6] 5.5 [4.5, 6] 5.5 [4.5, 6] <0.001 
  IADL, median [IQR] 5 [2, 8] 4 [1, 7] 5 [3, 8] 5 [3, 8] <0.001 
Cardiovascular risk factors      
  Ever smoker, n (%) 551 (35.8) 165 (38.3) 210 (34.9) 176 (34.6) 0.440 
  Hypertension, n (%) 1095 (71.1) 266 (61.7) 429 (71.4) 400 (78.7) <0.001 
Co-morbidities      
  Diabetes mellitus, n (%) 180 (11.7) 37 (8.6) 76 (12.6) 67 (13.2) 0.059 
  Atrial fibrillation, n (%) 218 (14.2) 67 (15.5) 82 (13.6) 69 (13.6) 0.621 
  Coronary heart disease, n (%) 361 (23.4) 103 (23.9) 144 (24.0) 114 (22.4) 0.809 
  Claudication, n (%) 94 (6.1) 27 (6.3) 35 (5.8) 32 (6.3) 0.934 
  Depression/anxiety, n (%) 762 (49.5) 218 (50.6) 293 (48.8) 251 (49.4) 0.845 
  Stroke/TIA, n (%) 258 (16.8) 79 (18.3) 96 (16.0) 83 (16.3) 0.579 
  Cancer, n (%) 136 (8.8) 48 (11.1) 51 (8.5) 37 (7.3) 0.108 
  Alcohol abuse, n (%) 62 (4.0) 14 (3.2) 28 (4.7) 20 (3.9) 0.520 
  Alzheimer’s dementia, n (%) 389 (25.3) 118 (27.4) 158 (26.3) 113 (22.2) 0.149 
  Parkinson’s disease, n (%) 22 (1.4) 12 (2.8) 2 (0.3) 8 (1.6) 0.004 
  Other neurod., n (%) 15 (1.0) 6 (1.4) 6 (1.0) 3 (0.6) 0.459 
  GFR, mL/min,  median [IQR] 64.9 [55.6, 
84.5] 
66.0 [55.5, 
85.4] 
64.8 [55.4, 
84.0] 
65.2 [55.9, 
84.1] 
0.765 
 
 
  
Table 1. Characteristics of study population according to tertile of systolic blood pressure 
(continues) 
Characteristic Total 
population 
Systolic blood pressure tertile p-value 
 n = 1,540 Low 
n=431 
Middle 
n=601 
High 
n=508 
 
Medications      
  On antihypertensives, n (%) 993 (64.5) 248 (57.5) 391 (65.1) 354 (69.7) 0.001 
  Anti-adrenergics, n (%) 58 (3.8) 9 (2.1) 18 (3.0) 31 (6.1) 0.002 
  Diuretics, n (%) 344 (22.3) 104 (24.1) 141 (23.5) 99 (19.5) 0.164 
  Beta-block., n (%) 139 (9.0) 37 (8.6) 49 (8.2) 53 (10.4) 0.390 
  Calcium-channel block., n (%) 370 (24.0) 88 (20.4) 155 (25.8) 127 (25.0) 0.113 
  ACE-inhibitors/AA, n (%) 566 (36.8) 129 (29.9) 217 (36.1) 220 (43.3) <0.001 
  Antipsychotics, n (%) 136 (8.8) 56 (13.0) 52 (8.7) 28 (5.5) <0.001 
  Anxiolytics, n (%) 404 (26.2) 103 (23.9) 164 (27.3) 137 (27.0) 0.427 
  Hypnotics/sedatives, n (%) 116 (7.5) 39 (9.0) 40 (6.7) 37 (7.3) 0.344 
  Antidepressants, n (%) 197 (12.8) 60 (13.9) 72 (12.0) 65 (12.8) 0.655 
N of medications, median [IQR] 3 [2, 5] 3 [2, 5] 3 [2, 5] 3.5 [2, 5] 0.219 
Abbreviations: n = number; IQR = inter quartile range; mmHg: millimeter of mercury; MMSE = Mini Mental 
State Examination; ADL = Activities of Daily Living; IADL = Instrumental Activities of Daily Living; TIA = 
transient ischemic attack; neurod = neurodegenerative; GFR= glomerular filtration rate; mL/min = 
millilitre/minute; block = blockers; ACE = angiotensin converting enzyme inhibitors; AA = angiotensin II 
antagonists. 
  
Table 2. MMSE score according to tertile of blood pressure 
  Tertiles   
 Low Middle High p-value 
SBP     
   n 431 601 508  
   Range of SBP (mmHg) 85 - 135 140 - 150 155 - 260  
   Mean SBP (SD) (mmHg) 124.3 (8.4) 144.3 (4.8) 169.5 (12.9)  
   MMSE score, mean (SE) 22.2 (0.3) 23.6 (0.3)* 24.2 (0.3)* <0.001 
DBP     
   n 307 737 496  
   Range of DBP (mmHg) 45 - 75 80 - 85 90 - 130  
   Mean DBP (SD) (mmHg) 69.1 (4.6) 80.7 (1.7) 93.7 (5.8)  
   MMSE score, mean (SE) 21.6 (0.4) 23.6 (0.2)* 24.1 (0.3)* <0.001 
PP     
   n 451 465 624  
   Range of PP (mmHg) 20 - 55 60 - 65 70 - 130  
   Mean PP (SD) (mmHg) 46.9 (6.2) 60.8 (1.8) 79.9 (11.0)  
   MMSE score, mean (SE) 22.9 (0.3) 23.1 (0.3) 23.9 (0.3)* 0.013 
MAP     
   n 476 544 520  
   Range of MAP (mmHg) 66.7 -98.3 100 – 108.3 110 – 173.3  
   Mean MAP (SD) (mmHg) 91.3 (5.7) 102.9 (2.9) 116.9 (7.6)  
   MMSE score, mean (SE) 22.3 (0.3) 23.6 (0.3)* 24.2 (0.3)* <0.001 
Abbreviations: mmHg: millimeter of mercury; MMSE: Mini Mental State Examination; SD: standard deviation; 
SE: standard error; SBP: systolic blood pressure; DBP: diastolic blood pressure; PP: pulse pressure; MAP: mean 
arterial pressure. MMSE scores are presented as unadjusted means (Standard Error). P-values are computed using 
blood pressure measures as continuous variables and are derived from the unadjusted model. *p-value<0.05 for 
difference between the low tertile and the middle/high tertile.
  
Table 3. Associations between blood pressure measures and Mini Mental State Examination score, stratified by age (starts) 
 75 – 79 years 
(n=534) 
80 – 84 years 
(n=497) 
85+ years 
(n=509) 
p-value for 
interaction 
 β-coefficient (95% CI) p-value β-coefficient (95% CI) p-value β-coefficient (95% CI) p-value  
SBP        
   Model 1a 0.17 [-0.11; 0.44] 0.235 0.27 [-0.02; 0.56] 0.065 0.73 [0.45; 1.01] <0.001 0.001 
   Model 2b 0.29 [0.04; 0.54] 0.025 0.23 [-0.06; 0.51] 0.114 0.64 [0.38; 0.90] <0.001 0.005 
   Model 3c 0.19 [-0.04; 0.42] 0.104 0.25 [0.01; 0.49] 0.045 0.44 [0.22; 0.66] <0.001 0.006 
   Model 4d 0.18 [-0.06; 0.43] 0.146 0.24 [-0.03; 0.51] 0.080 0.33 [0.10; 0.56] 0.005 0.146 
DBP        
   Model 1a 0.53 [-0.02; 1.09] 0.060 0.37 [-0.19; 0.94] 0.195 1.57 [0.96; 2.18] <0.001 <0.001 
   Model 2b 0.57 [0.05; 1.08] 0.030 0.23 [-0.32; 0.78] 0.407 1.27 [0.71; 1.83] <0.001 0.001 
   Model 3c 0.40 [-0.06; 0.85] 0.087 0.36 [-0.12; 0.83] 0.138 1.00 [0.53; 1.48] <0.001 0.002 
   Model 4d 0.30 [-0.20; 0.80] 0.244 0.32 [-0.20; 0.83] 0.230 0.91 [0.42; 1.40] <0.001 0.041 
 
  
  
Table 3. Associations between blood pressure measures and Mini Mental State Examination score, stratified by age (continues) 
PP        
   Model 1a 0.06 [-0.29; 0.41] 0.740 0.27 [-0.09; 0.64] 0.140 0.63 [0.28; 0.98] <0.001 0.036 
   Model 2b 0.25 [-0.08; 0.57] 0.137 0.26 [-0.09; 0.61] 0.150 0.57 [0.25; 0.89] 0.001 0.069 
   Model 3c 0.14 [-0.15; 0.43] 0.333 0.24 [-0.07; 0.54] 0.126 0.34 [0.07; 0.61] 0.013 0.061 
   Model 4d 0.18 [-0.14; 0.48] 0.268 0.23 [-0.10; 0.57] 0.170 0.20 [-0.09; 0.49] 0.172 0.438 
MAP        
   Model 1a 0.40 [-0.06; 0.85] 0.091 0.43 [-0.05; 0.90] 0.081 1.41 [0.92; 1.89] <0.001 <0.001 
   Model 2b 0.53 [0.10; 0.95] 0.015 0.32 [-0.15; 0.78] 0.181 1.19 [0.74; 1.64] <0.001 0.001 
   Model 3c 0.36 [-0.02; 0.74] 0.064 0.40 [-0.00; 0.80] 0.052 0.88 [0.50; 1.26] <0.001 0.001 
   Model 4d 0.31 [-0.11; 0.72] 0.146 0.37 [-0.07; 0.82] 0.099 0.73 [0.33; 1.13] <0.001 0.053 
Abbreviations: CI: confidence interval; SBP: systolic blood pressure; DBP: diastolic blood pressure; PP: pulse pressure; MAP: mean arterial pressure. Beta-coefficients 
represent change in Mini Mental State Examination score for each 10 mmHg increase in blood pressure measures. a Model 1: unadjusted. b Model 2: adjusted for age, sex and 
education. c Model 3: adjusted for age, sex, education, smoke, hypertension, diabetes mellitus, atrial fibrillation, coronary heart disease, claudication, depression/anxiety, history 
of transient ischemic attack or stroke, Alzheimer’s disease, present cancer, alcohol abuse, Parkinson’s disease, other neurodegenerative conditions, number of medication, anti-
adrenergics, diuretics, beta-blockers, calcium-channel blockers, angiotensin converting enzyme inhibitors/angiotensin II antagonists, antipsychotics, anxiolytics, sleep-inducers 
and sedatives, antidepressants. d Model 4: Model 3 plus glomerular filtration rate. 
  
Figure 1. MMSE score in tertiles of blood pressure stratified for ADL and IADL 
  
Figure 1. Bars represent unadjusted MMSE score means (with standard error). Abbreviations: MMSE = Mini 
Mental State Examination; ADL = Activities of Daily Living; IADL = Instrumental Activities of Daily Living; 
SBP = systolic blood pressure, DBP = diastolic blood pressure, PP = pulse pressure, MAP = mean arterial pressure. 
P-values for interaction indicate the interaction between blood pressure measures and ADL/IADL (interaction 
terms were calculated by multiplying continuous blood pressure measures by continuous ADL/IADL scores). The 
other p-values indicate the trend (linear regression). The symbol * indicates a significant difference between the 
low tertile and the middle/high tertile. The symbol # indicates a significant difference between the middle and 
high tertile. P-values for interaction, p-values for trend and differences between tertiles are computed in the 
unadjusted model. 
  
  
 
 
 
 
 
 
 
 
Chapter 3 
Blood pressure and mortality 
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ABSTRACT 
Background: optimal blood pressure targets in older adults are controversial. 
Objective: to investigate whether the relation of blood pressure with mortality in older adults 
varies by age, functional and cognitive status. 
Design: longitudinal geriatric outpatient cohort. 
Setting: Milan Geriatrics 75+ Cohort Study. 
Subjects: one thousand five hundred and eighty-seven outpatients aged 75 years and over. 
Methods: the relations of systolic (SBP) and diastolic blood pressure (DBP) with mortality 
risk were analysed using Cox proportional hazards models. Blood pressure, Mini-Mental State 
Examination (MMSE) and Basic Activities of Daily Living (ADL) were assessed at baseline. 
All analyses were adjusted for socio-demographic factors, co-morbidities and medications. 
Results: one thousand and forty-six patients died during 10-year follow-up. The relationships 
of SBP and DBP with mortality risk were U-shaped; SBP of 165 mmHg and DBP of 85 mmHg 
were associated with the lowest mortality. Patients with SBP < 120 mmHg and patients with 
SBP 120–139 mmHg had 1.64-fold (95% confidence intervals, CI 1.21–2.23) and 1.32-fold 
(95% CI 1.10–1.60) higher mortality risk than patients with SBP 160–179 mmHg (P values 
0.001 and 0.004, respectively). In patients with SBP below 180 mmHg, higher SBP was 
associated with lower mortality in patients with impaired ADL and MMSE but not in those 
with preserved ADL and/or MMSE (P for interaction 0.033). Age did not modify the 
correlation of SBP with mortality. 
Conclusions: the correlations of SBP and DBP with mortality were U-shaped. Higher SBP is 
related to lower mortality in subjects with impaired ADL and MMSE. ADL and MMSE may 
identify older subjects who benefit from higher blood pressure. 
 
  
  
INTRODUCTION 
The prevalence of hypertension increases with age, mainly due to rising systolic blood pressure 
(SBP)1. Hypertension is a leading risk factor for mortality, and its detection and control is a 
public health priority2. However, optimal treatment goals in frail older adults remain 
controversial3–5. 
The relation between blood pressure (BP) and mortality becomes complex in older adults. 
While in middle age higher BP is strongly and consistently associated with increased mortality 
risk, this association attenuates or even reverses when ageing6. A few studies showed a 
paradoxical increase in mortality with decreasing BP, thus suggesting a U-shaped 
relationship7,8. In addition, population-based studies indicated that chronological and 
biological age may affect the relation between BP and mortality, with lower BP being 
associated with increased mortality in the oldest and in the frailest9–14. An increased mortality 
risk in older adults with low BP may be a short-term phenomenon, attributable to co-morbidity 
and/or low BP in proximity of death, though reports are conflicting11, 12. Moreover, trials on 
the effect of antihypertensive drugs on mortality are conflicting; a meta-analysis showed no 
association between antihypertensives and overall mortality in adults ≥80 years15. Trials 
evidence on frailty impact is scarce5. 
Furthermore, the generalisability of data from trials or population-based studies to geriatric 
patients is debatable. Clinicians are confronted with a lack of data in outpatient populations, in 
which co-morbidities, functional and cognitive impairment may be more prevalent and severe 
and their interaction with BP and mortality more complex than in the general population. 
In the Milan Geriatrics 75+ Cohort Study, we recruited older outpatients with a wide range of 
functional and cognitive status and prospectively followed them for 10 years. In this study, we 
examined whether baseline BP was associated with all-cause mortality and whether this 
association varied by chronological age and levels of functional and cognitive impairment. 
 
  
  
METHODS 
Study Design and Participants 
The Milan Geriatrics 75+ Cohort Study is a prospective, hospital-based cohort study of the 
outpatients of the Geriatric Unit of ‘I.R.C.C.S. Ca’ Granda’ in Milan, Italy. Between 3 January 
2000 and 25 March 2004, 1,861 new consecutive outpatients aged ≥75 years attended a first 
comprehensive visit. Details of study design have been previously described16. After informed 
consent, the participants underwent a face-to-face standardised, structured, extensive medical 
assessment with trained physicians. After excluding participants with missing data on baseline 
BP (n = 200), other baseline covariates (n = 32) or mortality (n = 42), we included 1,587 
participants in this study. I.R.C.C.S. Ca’ Granda Ethics Committee approved the study. 
 
Blood pressure 
Physicians measured baseline arterial BP with a mercury sphygmomanometer, at heart level, 
in the seated position, after 5 min of rest and no vigorous exercise in the preceding 30 min. 
SBP and diastolic BP (DBP) were manually auscultated. Mean arterial pressure (MAP) was 
calculated as 1/3(SBP) + 2/3 (DBP) and pulse pressure (PP) as (SBP) − (DBP)6. 
 
Cognitive and functional status 
Cognitive function was assessed using the 30-item Mini-Mental State Examination (MMSE)17. 
Functional status was evaluated using Katz’ Activities of Daily Living (ADL) questionnaire18. 
ADL includes six items (rising or lying down, feeding, dressing, bathing, toileting, urinary and 
faecal continence). We defined impaired ADL as ADL score ≤ 5 and impaired MMSE as 
MMSE score ≤ 24 17, 18. 
 
 
 
  
Co-morbidities and life-style factors 
Hypertension was defined by a previous diagnosis. Coronary heart disease (CHD), history of 
transient ischaemic attack (TIA) or stroke, diabetes mellitus, atrial fibrillation, claudication and 
heart failure were proved by medical documents. Cardiovascular disease was defined by the 
presence of CHD, TIA/stroke or claudication. Cancer was defined by a diagnosis within the 
previous 5 years. Symptoms of anxiety/depression were self-reported or stated in medical 
documents. Smoking was dichotomised as never or ever (current and previous). Education was 
defined as years of school attended. 
 
Medications 
The number of medications was the number of drugs taken chronically or cyclically. 
Antihypertensives were defined by Anatomical Therapeutic Chemical classification codes C02 
(alpha-anti-adrenergics), C03 (diuretics), C07 (β-blockers), C08 (calcium-channel blockers) 
and C09 (angiotensinconverting enzyme (ACE) inhibitors/angiotensin II antagonists)19. 
 
Mortality 
All-cause mortality was assessed by collecting data from the Register Office of Milan or other 
town of residence. The follow-up period was the time between baseline and either death, loss 
to follow-up or 10-year period. 
 
Statistical analyses 
We performed Cox regression to estimate hazard ratios (HRs) and 95% confidence intervals 
(CI) for the association between BP measures and mortality. 
In all cohort, to test the presence of a non-linear association between BP measures and 
mortality, we entered BP measures and squared BP measures in the Cox regression as 
continuous variables. To gain clinical insight into these correlations, we run further analyses 
using BP measures as categorical variables. We classified participants into five SBP clinical 
  
categories (<120, 120–139, 140–159, 160–179 and ≥180 mmHg), four DBP categories (<80, 
80–89, 90–99 and ≥100 mmHg) and quintiles of MAP or PP. The categories associated with 
the lowest mortality risk were set as references. 
In participants with SBP below 180 mmHg (without hypertensive crisis)3, we tested the 
presence of a linear association between SBP and mortality. In this group, we explored the 
influence of chronological and biological age on the relationship between SBP and mortality. 
To evaluate the effect of chronological age, we performed Cox regression after categorising 
participants in three age strata (75–79, 80–84 and 85+ years). Furthermore, to assess the role 
of biological age as reflected in the functional/cognitive status, we repeated the analyses after 
stratifying participants according to: (i) ADL impairment (ADL score ≤ 5), (ii) MMSE 
impairment (MMSE score ≤ 24) or (iii) a combination of ADL/MMSE impairment (both 
impaired, either impaired, preserved)17, 18. We also carried out the analyses after stratifying 
participants by history of hypertension or cardiovascular disease. We tested for interaction by 
computing interaction terms using SBP as a continuous measure. Sensitivity analyses explored 
the influence of impaired cardiac function and imminent death, respectively, by excluding: (i) 
participants with heart failure at baseline or (ii) participants who died or were lost to follow-up 
in the first year. All analyses were also done for DBP. 
All analyses were performed in three steps. In Model 1, analyses were adjusted for age and sex. 
In Model 2, they were additionally adjusted for education, smoke, hypertension, diabetes 
mellitus, atrial fibrillation, CHD, claudication, TIA/stroke, depression/anxiety, cancer and 
number of medications. In Model 3, they were further adjusted for the use of antihypertensives. 
Analyses were performed using SPSS version 20.0.0 (SPSS Inc., Chicago, IL, USA). 
 
RESULTS 
Table 1 shows baseline characteristics of the study population. One thousand one hundred and 
fourteen (70.2%) participants were female, mean age was 82 years (range 75–101) and median 
SBP and DBP were 145 and 80 mmHg, respectively. One thousand and seventeen (64.1%) 
participants had a history of hypertension. Participants with higher SBP were more likely to be 
  
females, to have hypertension or to be treated with alpha-anti-adrenergics or ACE 
inhibitors/angiotensin II antagonists, while less likely to have CHD (all P < 0.05) 
(Supplementary Table 1). Similar associations with clinical characteristics were observed for 
DBP (Supplementary Table 2). 
After 10-year follow-up, 1,046 (65.9%) participants had died. The relationships of SBP, DBP, 
MAP and PP with mortality risk, respectively, were U-shaped (all P < 0.05). Mortality risk was 
lowest at SBP of 165 mmHg and at DBP of 85 mmHg. Figure 1 shows mortality risk in SBP 
and DBP categories. Participants with SBP < 120 mmHg and participants with SBP 120–139 
mmHg had a 1.64-fold (95% CI 1.21–2.23) and a 1.32-fold (95% CI 1.10–1.60) increased 
mortality risk than participants with SBP 160–179 mmHg (P values 0.001 and 0.004, 
respectively). Participants with DBP ≥ 100 mmHg had a 1.44-fold (95% CI 1.12–1.86) 
increased mortality risk than participants with DBP 90–99 mmHg (P value 0.004). Mortality 
risk in MAP and PP quintiles is illustrated in Supplementary Figure 1. 
When focusing on participants with SBP below 180 mmHg (n = 1,451), we observed an inverse 
linear relationship between SBP and mortality (Supplementary Table 3). In this group, each 10 
mmHg higher SBP was associated with a 0.87-fold (95% CI 0.77–0.99), a 0.91-fold (95% CI 
0.86–0.96) and a 0.92-fold (95% CI 0.88–0.96) decreased risk of mortality at 1-year, 5-year 
and 10-year follow-up, respectively (all P < 0.05). Age, history of hypertension or 
cardiovascular disease did not modify the association between SBP and mortality (P values for 
interaction = 0.653, 0.609 and 0.545, respectively). After stratifying for functional status, 
higher SBP was related to a decreased mortality risk in participants with impaired ADL, while 
not in those with preserved ADL (P values 0.001 and 0.085, respectively; P value for 
interaction = 0.093). Likewise, the association between higher SBP and decreased mortality 
risk was consistent in participants with impaired MMSE but not in those with preserved MMSE 
(P values 0.001 and 0.070, respectively; P value for interaction = 0.100). The relationship of 
SBP with mortality remained significant after exclusion of: (i) participants with heart failure at 
baseline (n = 145) or (ii) participants who died or were lost to follow-up in the first year (n = 
171). In participants with SBP below 180 mmHg, no association was observed between DBP 
and mortality (Supplementary Table 4). 
Figure 2 illustrates the relationship of SBP and DBP with 10-year mortality after stratifying 
participants for both functional and cognitive status. In participants with impairment in both 
  
ADL and MMSE, each 10-mmHg rise in SBP was related to a 0.89-fold (95% CI 0.83–0.96) 
decreased mortality risk. Conversely, no association was observed in participants with 
impairment in either ADL or MMSE (HR 0.94, CI 0.87–1.02) or in participants with preserved 
ADL and MMSE (HR 0.95, CI 0.87–1.03). Functional and cognitive status significantly 
modified the relationship of SBP with mortality (P for interaction = 0.033). Likewise, higher 
DBP tended to be more related with decreased mortality risk in participants with impaired ADL 
and/or MMSE and with increased mortality risk in those with preserved ADL and MMSE. 
 
DISCUSSION 
In this large longitudinal geriatric outpatient cohort, we reported two major findings. First, the 
association between BP and mortality risk was U-shaped with lowest mortality at SBP of 165 
mmHg. Second, the association between SBP and mortality varied by functional and cognitive 
status; higher SBP was correlated with increased survival especially in participants with 
impairment. These correlations were independent of cardiovascular risk factors, co-morbidities 
and medications. 
Our report of a mortality nadir at SBP of 165 mmHg is in line with results from a population-
based cohort of adults aged ≥ 85 years6. In our cohort, participants with SBP values in the 
optimal or normal range (<140 mmHg) presented increased mortality risk compared with those 
with SBP 160–179 mmHg. 
Our novel finding is that the association between SBP and mortality varies by biological age 
as defined by functional and cognitive status in geriatric outpatients. To our knowledge, the 
influence of biological age has been explored only in few population-based studies13, 14, 20. In 
the National Health and Nutrition Examination Survey, the association of BP with mortality 
varied by walking speed; elevated SBP was associated with a greater mortality risk among 
faster walkers while the association was reversed in the frailest participants who did not 
manage to complete the walking test13. In the Longitudinal Ageing Study Amsterdam, higher 
DBP was related to lower mortality risk in participants with a combination of physical and 
cognitive dysfunction (low walking speed and/or low MMSE score)14. In the Cardiovascular 
Health Study, DBP ≤ 65 mmHg correlated with the highest mortality risk in people with ADL 
  
impairment, whereas the association reversed in those without ADL impairment20. We did not 
observe similar associations, possibly due to a DBP distribution towards higher values in our 
cohort. 
Different explanations can be proposed. First, both low SBP and higher mortality risk could 
result from a common underlying cause, such as imminent death or impaired cardiac function21. 
Nonetheless, our estimates did not change after exclusion of participants who died in the first 
year of follow-up or those with heart failure. 
A second explanation is that hypoperfusion of vital organs such as the heart and the brain may 
link lower BP to increased mortality risk. Episodic hypotension has been associated with 
compromised coronary perfusion8 and markers of brain damage22, 23. The ageing brain may be 
more vulnerable to hypoperfusion during episodes of hypotension24. Conversely, higher SBP 
has been related to lower risk of stroke in adults over 85 years with physical and or cognitive 
impairment25. Consistently, in our cohort, the association of lower SBP and higher mortality 
was consistent in participants with impairment. 
Given the increasing life expectancy, it is crucial to explore whether the relationship of BP and 
mortality varies among heterogeneous old populations. Controversy persists on BP targets in 
adults over 80 years and in frail older adults3, 4. Findings from clinical trials are mixed. In the 
Hypertension in the Very Elderly Trial (HYVET), antihypertensive treatment, compared with 
placebo, reduced mortality in adults over 80 years with SBP ≥ 160 mmHg26. In HYVET, 
participants were treated with indapamide with or without perindopril to achieve the target BP 
of 150/80. Similarly, in STOP-Hypertension, therapy with β-blockers and a diuretic reduced 
mortality in adults aged 70–84 years, compared with placebo27. In contrast, in Syst-Eur, 
treatment starting with nitrendipine had no effect on mortality in adults over 60 years28. In 
Systolic Hypertension in the Elderly Program, treatment of isolated systolic hypertension with 
chlorthalidone was not associated with survival29. 
Furthermore, concern is growing on the generalisability of clinical trials. In HYVET, frailty 
did not modify treatment effects, but the definition of frailty did not consider the severity of 
impairments and dementia was an exclusion criterion5. The exclusion of people with severe 
co-morbidities or impairment from trials is proved by low mortality rates29. In a population-
based study, only 9% of the oldest with hypertension were eligible for inclusion in HYVET30. 
  
As the relationship of BP with mortality differs between fit and frail older adults, as suggested 
by our and other reports, the outcomes of the trials so far are difficult to generalise. 
The novelty of our study is to investigate the relationship between BP and mortality in an 
outpatient hospital-based cohort. A further asset is to show that ADL and MMSE— simple, 
common questionnaires—can identify adults who may benefit from higher BP. The 
observational design limits us in inferring causality. 
In conclusion, higher SBP is correlated with decreased mortality risk in adults with functional 
and cognitive impairment. BP management in older adults should be personalised using 
functional and cognitive status as markers of biological age. 
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Table 1. Baseline characteristics of study population 
Characteristic All cohort 
 n = 1,587 
Demographics  
  Age, years median [IQR] 82 [78; 86] 
  Females, n (%) 1114 (70.2) 
  Education, years, median [IQR] 7 [5; 11] 
Blood pressure  
  SBP, mmHg, median [IQR] 145 [130; 160] 
  DBP, mmHg, median [IQR] 80 [80; 90] 
Cardiovascular risk factors  
  Ever smoker, n (%) 566 (35.7) 
  Hypertension, n (%) 1017 (64.1) 
Functional/cognitive status  
  ADL score, median [IQR] 5.5 [4.5; 6] 
  MMSE score, median [IQR] 25 [20; 29] 
Co-morbidities  
  Diabetes mellitus, n (%) 194 (12.2) 
  Atrial fibrillation, n (%) 235 (14.8) 
  Coronary heart disease, n (%) 393 (24.8) 
  Claudication, n (%) 101 (6.4) 
  Depression/anxiety, n (%) 772 (48.6) 
  Stroke/TIA, n (%) 267 (16.8) 
  Cancer, n (%) 141 (8.9) 
  Heart failure, n (%) 153 (9.6) 
Drugs  
  Alpha-anti-adrenergics, n (%) 60 (3.8) 
  Diuretics, n (%) 369 (23.3) 
  Beta-blockers, n (%) 146 (9.2) 
  Calcium-channel blockers, n (%) 386 (24.3) 
  ACE-inhibitors/AA, n (%) 572 (36.0) 
N of drugs, median [IQR] 3 [2; 5] 
Abbreviations: n = number, IQR = inter quartile range, ADL = activities of daily living, MMSE = mini mental 
state examination, TIA = transient ischemic attack, ACE = angiotensin-converting-enzyme, AA = angiotensin II 
antagonists. 
  
  
Figure 1. Risk of 10-year mortality in SBP and DBP categories 
 
Bars represent hazard ratios (95% confidence interval). The category of SBP 160-179 mmHg and the category of 
DBP 90-99 mmHg were set as references in the left and right graph, respectively. The symbol * indicates a 
significant difference with the reference category. Analyses were adjusted for age, sex, education, smoke, 
hypertension, diabetes mellitus, atrial fibrillation, coronary heart disease, claudication, history of transient 
ischemic attack or stroke, depression/anxiety, cancer, number of medications, alpha-anti-adrenergics, diuretics, 
beta-blockers, calcium-channel blockers, angiotensin-converting-enzyme inhibitors/angiotensin II antagonists. 
Abbreviations: HR = hazard ratio, SBP = systolic blood pressure, DBP = diastolic blood pressure. Number of 
patients in each SBP category: SBP <120, n=74; SBP 120-139, n=376; SBP 140-159, n=647; SBP 160-179, 
n=354; SBP≥180, n=136. Number of patients in each DBP category: DBP <80, n=320; DBP 80-89, n=764; DBP 
90-99, n=364; DBP ≥100, n=139. 
  
  
Figure 2.  Risk of 10-year mortality for each 10mmHg increase in SBP / DBP stratified 
for functional and cognitive status 
 
Bars represent hazard ratios (95% confidence interval). Impaired ADL was defined as ADL score ≤ 5 and impaired 
MMSE as MMSE score ≤ 24. Analyses were adjusted for age, sex, education, smoke, hypertension, diabetes 
mellitus, atrial fibrillation, coronary heart disease, claudication, history of transient ischemic attack or stroke, 
depression/anxiety, cancer, number of medications, alpha-anti-adrenergics, diuretics, beta-blockers, calcium-
channel blockers, angiotensin-converting-enzyme inhibitors / angiotensin II antagonists. Abbreviations: HR = 
hazard ratio, SBP = systolic blood pressure, DBP = diastolic blood pressure, ADL = activities of daily living, 
MMSE = mini mental state examination. 
  
  
Supplementary Table 1. Baseline characteristics of study population in categories of 
systolic blood pressure 
Characteristic Systolic blood pressure categories (mmHg) p-
value <120 
n=74 
120 - 139 
n=376 
140 – 159 
n=647 
160 - 179 
n=354 
≥180 
n=136 
Demographics       
  Age, years median [IQR] 82 [78; 89] 82 [78; 87] 81 [78; 85] 82 [79; 87] 83 [79; 87] 0.092 
  Females, n (%) 54 (73.0) 252 (67.0) 433 (66.9) 276 (78.0) 99 (72.8) 0.003 
  Education, years, median 
[IQR] 
6 [5; 12] 7 [5; 12] 7 [5; 10] 6 [5; 10] 8 [5; 12] 0.857 
Cardiovascular risk factors       
  Ever smoker, n (%) 26 (35.1) 144 (38.3) 230 (35.5) 121 (34.2) 45 (33.1) 0.757 
  Hypertension, n (%) 42 (56.8) 195 (51.9) 409 (63.2) 259 (73.2) 112 (82.4) <0.001 
Functional/cognitive status       
  ADL score, median 
[IQR] 
4 [2.5; 5.5] 5.5 [4; 6] 5.5 [4.5; 6] 5.5 [4.5; 6] 5.5 [4.5; 6] <0.001 
  MMSE score, median 
[IQR] 
23 [15; 27] 25 [19; 28] 25 [21; 29] 26 [21; 29] 26 [22; 29] 0.004 
Co-morbidities, n (%)       
  Diabetes mellitus 5 (6.8) 33 (8.8) 86 (13.3) 51 (14.4) 19 (14.0) 0.064 
  Atrial fibrillation 15 (20.3) 59 (15.7) 97 (15.0) 46 (13.0) 18 (13.2) 0.527 
  Coronary heart disease 25 (33.8) 97 (25.8) 159 (24.6) 91 (25.7) 21 (15.4) 0.041 
  Claudication 7 (9.5) 26 (6.9) 40 (6.2) 20 (5.6) 8 (5.9) 0.777 
  Depression/anxiety 39 (52.7) 183 (48.7) 313 (48.4) 180 (50.8) 57 (41.9) 0.454 
  Stroke/TIA 16 (21.6) 66 (17.6) 103 (15.9) 56 (15.8) 26 (19.1) 0.644 
  Cancer 6 (8.1) 42 (11.2) 60 (9.3) 26 (7.3) 7 (5.1) 0.200 
  Heart failure 14 (18.9) 33 (8.8) 70 (10.8) 28 (7.9) 8 (5.9) 0.017 
Drugs, n (%)       
  Alpha-anti-adrenergics 1 (1.4) 8 (2.1) 19 (2.9) 21 (5.9) 11 (8.1) 0.002 
  Diuretics 22 (29.7) 95 (25.3) 157 (24.3) 68 (19.2) 27 (19.9) 0.131 
  Beta-blockers 6 (8.1) 32 (8.5) 56 (8.7) 34 (9.6) 18 (13.2) 0.514 
  Calcium-channel 
blockers 
9 (12.2) 90 (23.9) 165 (25.5) 88 (24.9) 34 (25.0) 0.161 
  ACE-inhibitors/AA 23 (31.1) 107 (28.5) 226 (34.9) 153 (43.2) 63 (46.3) <0.001 
N of drugs, median [IQR] 4 [2; 6] 3 [2; 5] 3 [2; 5] 4 [2; 5] 3 [1; 5] 0.092 
  
Abbreviations: n = number, IQR = inter quartile range, ADL = activities of daily living, MMSE = mini mental 
state examination, TIA = transient ischemic attack, ACE = angiotensin-converting-enzyme, AA = angiotensin II 
antagonists. P-values were computed using chi-squared test for categorical variables and Kruskal-Wallis test for 
continuous variables. 
  
Supplementary Table 2. Baseline characteristics of study population in categories of 
diastolic blood pressure 
Characteristic Diastolic blood pressure categories (mmHg) p-value 
 <80 
n=320 
80 - 89 
n=764 
90 – 99 
n=364 
≥100 
n=139 
 
Demographics      
  Age, years median [IQR] 82 [78; 87] 82 [78; 86] 82 [78; 86] 81 [78; 85] 0.462 
  Females, n (%) 212 (66.2) 537 (70.3) 260 (71.4) 105 (75.5) 0.208 
  Education, years, median [IQR] 6 [5; 10] 8 [5; 12] 6 [5; 10] 6 [5; 12] 0.162 
Cardiovascular risk factors      
  Ever smoker, n (%) 131 (40.9) 269 (35.2) 118 (32.4) 48 (34.5) 0.127 
  Hypertension, n (%) 174 (54.4) 470 (61.5) 262 (72.0) 111 (79.9) <0.001 
Functional/cognitive status      
  ADL score, median [IQR] 5 [3.5; 6] 5.5 [4.5; 6] 5.5 [4.5; 6] 5.5 [4.5; 6] <0.001 
  MMSE score, median [IQR] 25 [16; 28] 26 [21; 29] 26 [22; 29] 26 [21; 29] 0.001 
Co-morbidities, n (%)      
  Diabetes mellitus 39 (12.2) 91 (11.9) 48 (13.2) 16 (11.5) 0.930 
  Atrial fibrillation 60 (18.8) 98 (12.8) 59 (16.2) 18 (12.9) 0.064 
  Coronary heart disease 94 (29.4) 184 (24.1) 80 (22.0) 35 (25.2) 0.147 
  Claudication 30 (9.4) 47 (6.2) 19 (5.2) 5 (3.6) 0.057 
  Depression/anxiety 165 (51.6) 365 (47.8) 178 (48.9) 64 (46.0) 0.635 
  Stroke/TIA 60 (18.8) 141 (18.5) 48 (13.2) 18 (12.9) 0.065 
  Cancer 37 (11.6) 61 (8.0) 37 (10.2) 6 (4.3) 0.048 
  Heart failure 47 (14.7) 66 (8.6) 28 (7.7) 12 (8.6) 0.007 
Drugs, n (%)      
  Alpha-anti-adrenergics 8 (2.5) 21 (2.7) 20 (5.5) 11 (7.9) 0.004 
  Diuretics 81 (25.3) 193 (25.3) 64 (17.6) 31 (22.3) 0.028 
  Beta-blockers 33 (10.3) 59 (7.7) 42 (11.5) 12 (8.6) 0.179 
  Calcium-channel blockers 73 (22.8) 197 (25.8) 90 (24.7) 26 (18.7) 0.296 
  ACE-inhibitors/AA 100 (31.2) 272 (35.6) 136 (37.4) 64 (46.0) 0.023 
N of drugs, median [IQR] 4 [2; 5] 3 [2; 5] 3 [2; 5] 3 [2; 5] 0.181 
Abbreviations: n = number, IQR = inter quartile range, ADL = activities of daily living, MMSE = mini mental 
state examination, TIA = transient ischemic attack, ACE = angiotensin-converting-enzyme, AA = angiotensin II 
antagonists. P-values were computed using chi-squared test for categorical variables and Kruskal-Wallis test for 
continuous variables. 
  
Supplementary Table 3. Risk of mortality for each 10mmHg increase in systolic blood 
pressure 
 Model 1 Model 2 Model 3 
 HR [95% C.I.] p-value HR [95% C.I.] p-value HR [95% C.I.] p-value 
All participants       
  at 1-year 0.86 [0.77-0.97] 0.011 0.86 [0.76-0.98] 0.019 0.87 [0.77-0.99] 0.035 
  at 5-year 0.90 [0.85-0.94] <0.001 0.90 [0.85-0.95] <0.001 0.91 [0.86-0.96] 0.001 
  at 10-year 0.91 [0.88-0.95] <0.001 0.91 [0.88-0.95] <0.001 0.92 [0.88-0.96] <0.001 
Age strata*       
  75-79 years (n=500) 0.92 [0.85-1.00] 0.051 0.88 [0.81-0.97] 0.006 0.89 [0.81-0.97] 0.010 
  80-84 years (n=470) 0.94 [0.87-1.01] 0.083 0.95 [0.88-1.02] 0.131 0.95 [0.88-1.03] 0.204 
  85+ years (n=481) 0.87 [0.82-0.93] <0.001 0.88 [0.83-0.94] <0.001 0.88 [0.83-0.94] <0.001 
ADL strata*       
  ADL≤5 (n=594) 0.90 [0.86-0.95] <0.001 0.90 [0.86-0.96] <0.001 0.91 [0.86-0.96] 0.001 
  ADL>5 (n=802) 0.95 [0.89-1.01] 0.119 0.94 [0.88-1.01] 0.079 0.94 [0.88-1.01] 0.085 
MMSE strata*       
  MMSE≤24 (n=586) 0.89 [0.84-0.94] <0.001 0.90 [0.85-0.95] <0.001 0.90 [0.85-0.96] 0.001 
  MMSE>24 (n=765) 0.95 [0.90-1.01] 0.098 0.94 [0.89-1.00] 0.064 0.94 [0.89-1.01] 0.070 
Hypertension strata*       
  Without (n=546) 0.90 [0.84-0.96] 0.002 0.89 [0.83-0.96] 0.002 0.89 [0.83-0.96] 0.003 
  With (n=905) 0.91 [0.86-0.95] <0.001 0.91 [0.87-0.96] <0.001 0.92 [0.87-0.97] 0.001 
CVD strata*       
  Without (n=880) 0.91 [0.86-0.96] 0.001 0.90 [0.85-0.95] <0.001 0.91 [0.86-0.96] 0.001 
  With (n=571) 0.92 [0.86-0.97] 0.003 0.93 [0.87-0.98] 0.013 0.93 [0.88-0.99] 0.033 
Restricted samples       
No heart failure* 
(n=1306) 
0.91 [0.87-0.95] <0.001 0.91 [0.87-0.95] <0.001 0.91 [0.87-0.95] <0.001 
First year survivors* 
(n=1280) 
0.92 [0.88-0.96] <0.001 0.92 [0.88-0.96] <0.001 0.92 [0.88-0.96] <0.001 
aModel 1: adjusted for age and sex; bModel 2: age, sex, education, ever smoker, number of medications, 
hypertension, diabetes mellitus, atrial fibrillation, coronary heart disease, claudication, history of transient 
ischemic attack or stroke, depression/anxiety, cancer; cModel 3: age, sex, education, smoke, hypertension, diabetes 
mellitus, atrial fibrillation, coronary heart disease, claudication, history of transient ischemic attack or stroke, 
depression/anxiety, cancer, number of medications, alpha-anti-adrenergics, diuretics, beta-blockers, calcium-
channel blockers, angiotensin-converting-enzyme inhibitors/angiotensin II antagonists. Abbreviations: HR = 
hazard ratio, CI = confidence interval, SBP = systolic blood pressure, CVD = cardiovascular disease. The symbol 
* indicates hazard ratio for 10-year mortality risk. 
  
Supplementary Table 4. Risk of mortality for each 10mmHg increase in diastolic blood 
pressure 
 Model 1 Model 2 Model 3 
 HR [95% C.I.] p-value HR [95% C.I.] p-value HR [95% C.I.] p-value 
All participants       
  at 1-year 0.86 [0.70-1.06] 0.164 0.85 [0.68-1.07] 0.171 0.86 [0.68-1.08] 0.186 
  at 5-year 0.95 [0.86-1.05] 0.294 0.98 [0.89-1.09] 0.741 0.99 [0.90-1.09] 0.839 
  at 10-year 0.95 [0.89-1.03] 0.190 0.98 [0.91-1.06] 0.580 0.98 [0.91-1.06] 0.634 
Age strata*       
  75-79 years (n=500) 0.94 [0.81-1.09] 0.428 0.94 [0.81-1.10] 0.440 0.95 [0.81-1.11] 0.528 
  80-84 years (n=470) 1.02 [0.90-1.16] 0.795 1.07 [0.93-1.22] 0.357 1.07 [0.94-1.23] 0.307 
  85+ years (n=481) 0.91 [0.81-1.02] 0.093 0.90 [0.80-1.01] 0.070 0.89 [0.79-1.00] 0.054 
ADL strata*       
  ADL≤5 (n=594) 0.93 [0.85-1.03] 0.186 0.95 [0.86-1.06] 0.368 0.96 [0.87-1.07] 0.454 
  ADL>5 (n=802) 1.00 [0.89-1.11] 0.944 1.03 [0.92-1.15] 0.617 1.03 [0.92-1.15] 0.648 
MMSE strata*       
  MMSE≤24 (n=586) 0.93 [0.84-1.03] 0.172 0.97 [0.87-1.08] 0.572 0.97 [0.87-1.08] 0.550 
  MMSE>24 (n=765) 1.03 [0.92-1.16] 0.592 1.04 [0.92-1.17] 0.552 1.04 [0.92-1.17] 0.521 
Hypertension strata*       
  Without (n=546) 0.92 [0.81-1.05] 0.224 0.96 [0.84-1.10] 0.577 0.96 [0.84-1.10] 0.576 
  With (n=905) 0.95 [0.87-1.04] 0.248 0.97 [0.88-1.06] 0.481 0.97 [0.89-1.07] 0.565 
CVD strata*       
  Without (n=880) 0.98 [0.89-1.09] 0.758 0.98 [0.89-1.09] 0.732 0.98 [0.89-1.09] 0.747 
  With (n=571) 0.93 [0.83-1.04] 0.181 0.98 [0.87-1.10] 0.721 0.98 [0.87-1.10] 0.718 
Restricted samples       
No heart failure* 
(n=1306) 
0.96 [0.88-1.04] 0.297 0.98 [0.90-1.06] 0.570 0.98 [0.90-1.07] 0.610 
First year survivors* 
(n=1280) 
0.97 [0.89-1.05] 0.387 1.00 [0.92-1.08] 0.965 1.00 [0.92-1.08] 0.996 
aModel 1: adjusted for age and sex; bModel 2: age, sex, education, ever smoker, number of medications, 
hypertension, diabetes mellitus, atrial fibrillation, coronary heart disease, claudication, history of transient 
ischemic attack or stroke, depression/anxiety, cancer; cModel 3: age, sex, education, smoke, hypertension, diabetes 
mellitus, atrial fibrillation, coronary heart disease, claudication, history of transient ischemic attack or stroke, 
depression/anxiety, cancer, number of medications, alpha-anti-adrenergics, diuretics, beta-blockers, calcium-
channel blockers, angiotensin-converting-enzyme inhibitors/angiotensin II antagonists. Abbreviations: HR = 
hazard ratio, CI = confidence interval, DBP = systolic blood pressure, CVD = cardiovascular disease. The symbol 
* indicates that we report hazard ratio for 10-year mortality risk.  
  
  
Supplementary Figure 1. Risk of 10-year mortality in MAP and PP quintiles 
 
Bars represent hazard ratios (95% confidence interval). The category of MAP 106-113 mmHg and the category 
of PP 70-75 mmHg were set as references in the left and right graph, respectively. The symbol * indicates a 
significant difference with the reference category. Analyses were adjusted for age, sex, education, smoke, 
hypertension, diabetes mellitus, atrial fibrillation, coronary heart disease, claudication, history of transient 
ischemic attack or stroke, depression/anxiety, cancer, number of medications, alpha-anti-adrenergics, diuretics, 
beta-blockers, calcium-channel blockers, angiotensin-converting-enzyme inhibitors/angiotensin II antagonists. 
Abbreviations: HR = hazard ratio, MAP = mean arterial blood pressure, PP = pulse pressure. Number of patients 
in MAP quintiles from first to fifth: n=325; n=407; n=171; n=405; n=279. Number of patients in PP quintiles 
from first to fifth: n=406; n=70; n=469; n=291; n=351. 
  
  
 
 
 
 
 
 
 
 
 
Chapter 4 
Thyroid status and mortality 
 
 
 
 
 
Manuscript based on this chapter has been submitted as: 
Ogliari G, Smit RA, van der Spoel E, Mari D, Torresani E, Felicetta I, Lucchi TA, Rossi PD, 
van Heemst D, de Craen AJ, Westendorp RG. Thyroid status and mortality risk in euthyroid 
older adults: sex-differences in the Milan Geriatrics 75+ Cohort Study. 
  
  
ABSTRACT 
Background: Optimal thyroid status in old age is controversial. This study investigated the 
longitudinal association between thyroid parameters and 10-year all-cause mortality risk in 
euthyroid older outpatients according to sex and age. 
Methods: Baseline thyrotropin (TSH), free thyroxine (fT4) and free triiodothyronine (fT3) 
were assessed in the Milan Geriatrics 75+ Cohort Study. 338 men and 630 women aged over 
75 years were euthyroid. Hazard ratios (HRs) and 95% confidence intervals (CI) were 
calculated for the associations of TSH, fT4 and fT3 with mortality risk using Cox regression. 
Analyses were stratified by sex and adjusted for socio-demographic factors and co-morbidities. 
Results: 245 men and 382 women died during follow-up. After adjustment, each 1 mU/L 
higher TSH was associated with decreased mortality risk in men (HR 0.81, 95% CI 0.68-0.96), 
but not in women (HR 1.09, 95% CI 0.96-1.23) (p for sex-difference = 0.002). Each 1 ng/L 
higher fT4 was associated with increased mortality risk in men (HR 1.12, 95% CI 1.03-1.21), 
whereas not in women (HR 0.99, 95% CI 0.94-1.04) (p for sex-difference = 0.008). Each 1 
pg/mL higher fT3 was associated with decreased mortality risk in both men (HR 0.78, 95% CI 
0.55-1.10) and women (HR 0.78, 95% CI 0.62-0.99). The inverse association between TSH 
and mortality was most pronounced in men aged over 85 years. 
Conclusions: Among euthyroid older outpatients, higher TSH and lower fT4 were associated 
with decreased mortality risk in men but not in women. When assessing thyroid status, sex and 
age should be taken into account. 
  
  
INTRODUCTION 
Thyroid status can be assessed by measuring serum thyrotropin (TSH), free thyroxine (fT4) 
and free triiodothyronine (fT3). Optimal thyroid status in old age, particularly the normal TSH 
reference range, is controversial1,2. Lowering TSH upper reference limit from 4.00 to 2.50 
mU/L is highly debated3, as TSH distribution progressively shifts towards higher values with 
aging4. This shift may arise from a higher prevalence of occult thyroid disease; indeed, 
euthyroid adults with higher TSH have an increased risk of hypothyroidism5. Alternatively, 
this shift may result from selective survival of individuals with constitutively lower thyroid 
status. Indeed, exceptionally long-lived adults and their offspring exhibit higher normal TSH 
with unchanged fT4, possibly indicative of a different set-point of the pituitary-thyroid axis6. 
A genetic influence on thyroid status is also supported by twin studies7 and by the observation 
that intra-individual variation in thyroid status is smaller than inter-individual variation8. In 
addition, sex may modulate the effect of several genetic variants for TSH and fT4 levels9. 
TSH, fT4 and fT3 have profound and pleiotropic effects on aging individuals, by influencing 
metabolism, cardiovascular function and mental health10. These effects may differ in men and 
women10,11. Furthermore, the relationship between TSH and mortality risk in euthyroid adults 
is unclear, with some studies reporting no association12,13 and others an inverse association14-
18 . The relationship of fT4 and fT3 with mortality risk is ambiguous12,15,19. Finally, most current 
evidence is from population-based studies on adults with wide age ranges, which limits their 
generalizability. Data are lacking on older outpatients, a potentially diverse population, whom 
clinicians encounter in everyday clinical practise. Older outpatients may present a higher 
burden of comorbidities, in a complex interplay with thyroid status.  
Therefore, we assessed the association between thyroid status and mortality risk in euthyroid 
older men and women enrolled in the Milan Geriatrics 75+ Cohort Study, a longitudinal 
geriatric outpatient cohort. Furthermore, we investigated whether it differs by sex and age. 
 
 
 
 
  
METHOD 
Study Design and Participants 
The Milan Geriatrics 75+ Cohort Study is a prospective hospital-based cohort study of the 
outpatients of the Geriatric Unit of ‘’I.R.C.C.S. Ca’ Granda’’ in Milan, Italy. Between 3 
January 2000 and 25 March 2004, 1861 new consecutive outpatients aged 75 years and over 
attended a first face-to-face, standardized, structured, comprehensive visit with trained 
physicians, after informed consent. Details of study design were previously described20. 
To explore the association between the natural course of euthyroid function, unmodified by 
medical intervention, and mortality, we excluded participants on thyroid medications (n=74), 
and those with baseline TSH < 0.20 mU/L or > 4.00 mU/L or missing (n=768). Additionally, 
we excluded participants with missing data on mortality at follow-up (n=51). Therefore, we 
included 968 euthyroid participants in the present analysis. These included participants were 
younger and more likely to be men, smokers and to have depression/anxiety compared to the 
excluded participants (data not shown). Of the included participants, 761 and 708 participants, 
respectively, had available data on fT4 and fT3; we performed our analyses on fT4 and fT3 in 
those with values within the reference range (n=736 and n=651, respectively). The study was 
approved by I.R.C.C.S. Ca’ Granda Ethics Committee. 
 
Thyroid parameters 
Blood for baseline measurements was drawn in the morning, after an overnight fast. TSH, fT4 
and fT3 were measured in serum using chemiluminescent assays (Immulite 2000, Medical 
Systems). IRCCS Ca’ Granda Laboratory reference ranges were 0.20-4.00 mU/L for TSH, 8.0-
18.0 ng/L for fT4 and 2.0-4.8 pg/mL for fT3. 
 
Co-morbidities and life-style factors 
Baseline data on history of hypertension, diabetes mellitus, coronary heart disease (CHD), 
transient ischemic attack (TIA) or stroke, atrial fibrillation, claudication and heart failure were 
obtained from medical documents. Cancer was defined as a diagnosis within the previous five 
years. Symptoms of anxiety/depression were self-reported or stated in medical documents. 
  
Smoking was dichotomized as never or ever (current and previous). Education was defined as 
years of school attended. Number of medications was the number of drugs taken chronically 
or cyclically. 
 
Mortality 
All-cause mortality was assessed through the Register Office of Milan or other town of 
residence. The follow-up period was the time between baseline and either death, loss to follow-
up or 10-year period. 
 
Statistical analyses 
Baseline characteristics were reported as mean (standard deviation, SD) for continuous 
variables and number (percentage) for categorical variables. Differences in baseline 
characteristics between sexes or across TSH quartiles were assessed using Student’s t-test, one-
way ANOVA or chi-square test where appropriate. We checked whether fT4 was inversely 
associated with the logarithm of TSH in our cohort, as previously shown in the literature21, 
using linear regression. 
We performed Cox regression to estimate hazard ratios (HRs) and 95% confidence intervals 
(CI) for the association of TSH, fT4 and fT3, respectively, with mortality risk in men and 
women, separately. First, we tested the presence of linear associations between thyroid 
parameters and mortality risk. Second, we checked the presence of non-linear associations, by 
entering thyroid parameters and squared thyroid parameters in the Cox regression as 
continuous variables. Third, we performed additional analyses using quartiles of TSH, fT4 and 
fT3. Finally, we ran further analyses using three categories of TSH values, which were defined 
according to clinical cut-offs (TSH 0.20-0.39; TSH 0.40-2.50; TSH 2.51-4.00 mU/L)2,22. 
To explore sex-differences in the relationship between thyroid parameters and mortality risk, 
we computed interaction terms by multiplying thyroid parameters, as continuous variables, by 
sex. 
Furthermore, we examined the association between thyroid parameters and mortality risk 
within three age strata (75–79, 80–84, ≥85 years). We tested for interaction between thyroid 
  
parameters and age, in men and women, separately. Moreover, we checked for sex-differences 
within age strata. 
We performed sensitivity analyses after exclusion of participants who were on medications 
potentially affecting thyroid function (amiodar or lithium) or who had a history of thyroid 
disease. Furthermore, we performed sensitivity analyses for the association of TSH with 
mortality risk restricted to those participants with both fT4 and fT3 within the reference range. 
All analyses were performed in two steps. In Model 1, analyses were adjusted for age. In Model 
2, they were additionally adjusted for education, smoking, hypertension, diabetes mellitus, 
atrial fibrillation, CHD, claudication, stroke/TIA, depression/anxiety, cancer and number of 
medications. Analyses were performed using SPSS version 20.0.0 (SPSS Inc., Chicago, IL). 
 
RESULTS 
Table 1 shows the baseline characteristics of the participants by sex and across quartiles of 
TSH. In the cohort, mean age was 82 years (range 75-98) and 630 (65.1%) participants were 
women. Mean TSH, fT4 and fT3 were 1.7 mU/L, 12.2 ng/L and 2.9 pg/mL, respectively, and 
did not differ by sex (all p-values > 0.05). Men were more educated, more likely to be smokers, 
to have atrial fibrillation, CHD, claudication, stroke/TIA or cancer, while less likely to have 
depression/anxiety compared to women (all p-values < 0.05). Baseline characteristics of men 
did not differ across quartiles of TSH. In contrast, women with higher TSH were more likely 
to have a history of stroke/TIA (p-value = 0.004). 
We observed an inverse relationship between fT4 and the logarithm of TSH in both men (β= -
0.144, 95% CI -0.291;-0.002, p=0.054) and women (β= -148, 95% CI -0.248;-0.047, p=0.004). 
After 10-year follow-up, 245 (72.5%) men and 382 (60.6%) women had died. At 10-year 
follow-up, higher TSH and lower fT4 were linearly associated with decreased mortality risk in 
men, whereas higher fT3 was linearly associated with decreased mortality risk in women (all 
p-values < 0.05, Figure 1). At 10-year follow-up, no U-shaped associations were observed (all 
p-values for quadratic associations >0.05). 
In contrast, the association between TSH and 5-year mortality risk in women was U-shaped, 
even after full adjustment (p-value for quadratic association = 0.009, Supplementary Figure 1). 
  
All other associations at 1-year and 5-year follow-up were similar to those observed at 10-year 
follow-up (Supplementary Table 1). 
Figure 2 shows the effect of sex on the associations of TSH, fT4 and fT3 with 10-year mortality 
risk. Sex significantly modified the associations of TSH and fT4 with mortality. After full 
adjustment, each 1 mU/L higher TSH was associated with a 0.81-fold (95% CI 0.68-0.96, p = 
0.013) decreased mortality risk in men, whereas not in women (HR 1.09, 95% CI 0.96-1.23, p 
= 0.206) (p for sex-difference = 0.002). Likewise, each 1 ng/L higher fT4 was associated with 
a 1.12-fold (95% CI 1.03-1.21, p = 0.008) increased mortality risk in men, whereas not in 
women (HR 0.99, 95% CI 0.94-1.04, p = 0.660) (p for sex-difference = 0.008). No sex-
difference was observed in the relationship between fT3 and mortality. Each 1 pg/mL higher 
fT3 was associated with decreased mortality risk in men (HR 0.78, 95% CI 0.55-1.10, p =0.151) 
and women (HR 0.78, 95% CI 0.62-0.99, p = 0.037). 
Figure 3 illustrates the influence of age on the association between TSH and mortality risk at 
10-year follow-up. After full adjustment, each 1 mU/L increase in TSH was associated with a 
0.77-fold (95% CI 0.55-1.08, p = 0.125) and with a 0.63-fold (95% CI 0.46-0.87, p = 0.006) 
decreased mortality risk in men aged 80-84 years and 85 years and over, respectively. In 
contrast, the association tended to revert in men aged 75-79 years (HR 1.12, 95% CI 0.82-1.52, 
p = 0.495). In men, interaction by age was significant (p = 0.006). In women, we observed 
neither association between TSH and mortality risk in any age strata nor interaction by age. 
Sex-differences in the relationship between TSH and mortality risk were not present in 
participants aged 75-79 years (p = 0.769), whereas they appeared in those aged 80-84 (p = 
0.042) and 85 years and over (p = 0.004) (Figure 3). 
We found no interaction by age in the relationships of fT4 and fT3 with mortality risk in either 
men or women (all p > 0.05, data not shown). 
Figure 4 shows the association between clinical categories of TSH and 10-year mortality risk 
by sex. After full adjustment, men with TSH 2.51-4.00 mU/L had a 0.61-fold (95% CI 0.41-
0.92, p = 0.017) decreased mortality risk than men in the middle category. In contrast, women 
with TSH 2.51-4.00 mU/L had a 1.19-fold (95% CI 0.90-1.56, p = 0.221) increased mortality 
risk than women in the middle category. 
  
The results did not materially change in sensitivity analyses after exclusion of participants 
taking amiodar (n=22), lithium (n=1) or with previous thyroid disease (n=12) (data not shown). 
Likewise, the association between TSH and mortality risk remained essentially unchanged 
when restricting the analyses to participants with both fT4 and fT3 within the reference range 
(n=632) (data not shown). 
 
DISCUSSION 
Among euthyroid older adults in an outpatient setting, higher TSH and lower fT4 were 
associated with decreased mortality risk in men, but not in women. The associations of TSH 
and fT4 with mortality risk significantly differed by sex. The inverse association between TSH 
and mortality risk was most pronounced in men aged 85 years and over. All associations were 
independent of cardiovascular risk factors and comorbidities. 
Our finding of an inverse relationship between TSH and mortality risk in men is in line with 
previous population-based studies in older adults14-18, whereas others showed no 
association12,13. The discrepancies among studies may result from differences in the age- and 
sex- structure of the studied populations. Indeed, the novelty of our study is to report sex-
differences in the relationship between TSH and mortality risk. 
Why does sex modify the relationship between thyroid status and mortality? First, women 
compared to men have higher prevalence and incidence of subclinical and overt thyroid 
dysfunctions, which have been associated with an excess of mortality23-25. TSH values at the 
upper and lower limits of our laboratory reference range may reflect occult thyroid diseases in 
women, while not in men. Our finding of a U-shaped relationship between TSH and mortality 
risk at 5-year follow-up only in women is consistent with this hypothesis. Second, sex modifies 
the relationship between morbidity and mortality26. Women live longer than men, by surviving 
diseases that are fatal in men26. 
High normal thyroid status, as characterised by lower TSH and higher fT4 within the reference 
range, has been linked to adverse health outcomes10. These may result from different 
pathophysiological mechanisms, including increased metabolic rate and altered cardiovascular 
hemodynamic27. High normal thyroid status has been linked to increased heart rate and incident 
atrial fibrillation, which in turn are associated with functional decline and mortality22,28-29. 
  
Higher fT4 has also been directly related to frailty in euthyroid community-dwelling older 
men19,30. 
Furthermore, high normal thyroid status may affect brain structure and function. High thyroid 
status may favour thromboembolism and brain vascular damage through a combination of atrial 
fibrillation, endothelial dysfunction and hypercoagulability23. Alternatively, it may directly 
cause neurodegeneration through increased oxidative stress23. However, controversy persists 
on the association between thyroid status and cognitive impairment and dementia, which, in 
turn, have been associated with increased mortality risk31-34. 
High normal thyroid status may be particularly detrimental in older adults with cardiovascular 
comorbidities27. Consistent with this hypothesis, in our cohort, lower TSH and higher fT4 were 
associated with increased mortality risk in men, especially the oldest men, who presented more 
cardiovascular comorbidities compared to women. However, sex-differences in our study 
remained significant after adjustment for comorbidities. 
An alternative explanation to our findings may be that the set-point of the pituitary-thyroid axis 
is shifted towards higher TSH values in adults with genetic predisposition to longevity6. Men 
aged over 85 years in our study had above-average life-expectancy, thus suggesting a genetic 
longevity trait35. Animal studies have suggested a causal relationship between lower thyroid 
status and extended life span36. Lower thyroid status may extend life span by lowering 
metabolic rate and core body temperature, which in turn results in lower generation of reactive 
oxygen species and oxidative stress36. Other mechanisms may include effects on membrane 
composition, inflammation and stem cell renewal37. 
Our finding of an association between lower fT3 and increased mortality risk is in line with 
The Aging in the Chianti Area Study, which included Italians aged 65 years and over15. Lower 
fT3 in euthyroid older individuals may be indicative of non-thyroidal systemic illnesses15,38. 
Our study has relevant clinical implications. First, clinicians should take into account both sex 
and age when assessing thyroid status. Furthermore, we reported that older men with TSH 2.51 
– 4.00 mU/L had a 0.61-fold decreased mortality risk than those with TSH 0.40 – 2.50 mU/L. 
This observational finding conflicts with the indication of lowering TSH upper reference limit, 
at least in older men2. 
  
Moreover, clinical trials on the clinical benefits or harms of lowering TSH upper reference 
limit in older adults are lacking39. Furthermore, clinical trials recruit selected populations, 
which limits their generalizability39. 
A major strength of our study is our unselected population of older geriatric outpatients, which 
makes our findings generalizable in common clinical practice. A further asset is the 
longitudinal design, with a long follow-up. However, the observational nature of our study 
limits us in inferring causality. Furthermore, a single measurement of thyroid status was used 
in the analyses, potentially leading to misclassification of subjects. However, previous research 
has demonstrated that intra-individual variability of thyroid status is narrow and less than inter-
individual variability8. In addition, this misclassification would be random and merely lead to 
underestimation of true associations. 
In conclusion, higher TSH and lower fT4 within the reference ranges were associated with 
decreased mortality risk in men but not in women. Our findings add to the current debate on 
TSH reference limits. Further research is needed to establish whether the relationship between 
thyroid status and mortality is causal. 
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Table 1. Characteristics of study population at baseline 
 Quartiles of TSH (mU/L)  
Characteristics All First 
0.24-1.02 
Second 
1.03-1.55 
Third 
1.56-2.16 
Fourth 
2.17-3.98 
p-
value 
Men n=338 n=89 n=89 n=89 n=71  
Demographics, years, mean (SD)       
  Age 81.6 (4.6) 81.5 (4.3) 81.2 (4.4) 81.6 (4.8) 82.3 (4.9) 0.523 
  Education 9.8 (5.0) 9.3 (4.6) 9.6 (5.0) 9.7 (5.2) 11.2 (5.0) 0.101 
Risk factors/ comorbidities, n (%)       
  Ever smoker 228 (67.5) 64 (71.9) 61 (68.5) 56 (62.9) 47 (66.2) 0.629 
  Hypertension 222 (65.7) 62 (69.7) 55 (61.8) 57 (64.0) 48 (67.6) 0.695 
  Diabetes mellitus 53 (15.7) 15 (16.9) 16 (18.0) 12 (13.5) 10 (14.1) 0.823 
  Atrial fibrillation 62 (18.3) 9 (10.1) 18 (20.2) 19 (21.3) 16 (22.5) 0.132 
  Coronary heart disease 98 (29.0) 26 (29.2) 23 (25.8) 26 (29.2) 23 (32.4) 0.842 
  Claudication 34 (10.1) 13 (14.6) 6 (6.7) 10 (11.2) 5 (7.0) 0.265 
  Depression or anxiety 136 (40.2) 46 (51.7) 35 (39.3) 30 (33.7) 25 (35.2) 0.066 
  Stroke or TIA 66 (19.5) 19 (21.3) 21 (23.6) 15 (16.9) 11 (15.5) 0.519 
  Cancer 53 (15.7) 15 (16.9) 11 (12.4) 15 (16.9) 12 (16.9) 0.799 
  Heart failure 35 (10.4) 5 (5.6) 11 (12.4) 7 (7.9) 12 (16.9) 0.093 
N of drugs, mean (SD) 3.8 (2.4) 3.8 (2.5) 3.7 (2.3) 3.4 (2.4) 4.1 (2.4) 0.322 
fT4 (ng/L), mean (SD) 12.0 (2.1) 12.3 (2.2) 12.1 (1.9) 12.0 (1.9) 11.4 (2.2) 0.147 
fT3 (pg/mL), mean (SD) 2.9 (0.5) 2.9 (0.5) 2.9 (0.6) 2.9 (0.5) 2.9 (0.6) 0.995 
Women n=630 n=152 n=152 n=155 n=171  
Demographics, years, mean (SD)       
  Age 82.2 (4.9) 82.4 (4.6) 82.2 (4.8) 81.4 (5.2) 82.8 (4.8) 0.074 
  Education 6.9 (3.8) 6.3 (3.3) 7.2 (3.7) 6.9 (3.8) 7.3 (4.3) 0.082 
Risk factors/ comorbidities, n (%)       
  Ever smoker 146 (23.2) 29 (19.1) 33 (21.7) 41 (26.5) 43 (25.1) 0.404 
  Hypertension 445 (70.6) 113 (74.3) 100 (65.8) 109 (70.3) 123 (71.9) 0.412 
  Diabetes mellitus 74 (11.7) 17 (11.2) 17 (11.2) 19 (12.3) 21 (12.3) 0.981 
  Atrial fibrillation 80 (12.7) 13 (8.6) 19 (12.5) 21 (13.5) 27 (15.8) 0.268 
  Coronary heart disease 132 (21.0) 33 (21.7) 25 (16.4) 29 (18.7) 45 (26.3) 0.148 
  Claudication 30 (4.8) 7 (4.6) 7 (4.6) 4 (2.6) 12 (7.0) 0.313 
  Depression or anxiety 356 (56.5) 80 (52.6) 88 (57.9) 94 (60.6) 94 (55.0) 0.514 
  Stroke or TIA 83 (13.2) 13 (8.6) 21 (13.8) 14 (9.0) 35 (20.5) 0.004 
  Cancer 41 (6.5) 7 (4.6) 15 (9.9) 7 (4.5) 12 (7.0) 0.186 
  Heart failure 50 (7.9) 12 (7.9) 14 (9.2) 10 (6.5) 14 (8.2) 0.845 
N of drugs, mean (SD) 3.5 (2.3) 3.3 (2.2) 3.4 (2.3) 3.4 (2.3) 3.9 (2.3) 0.115 
fT4 (ng/L), mean (SD) 12.3 (2.1) 12.6 (1.9) 12.3 (2.2) 12.5 (2.3) 11.8 (2.1) 0.026 
fT3 (pg/mL), mean (SD) 3.0 (0.5) 2.9 (0.5) 3.0 (0.5) 3.0 (0.6) 3.0 (0.6) 0.456 
P-values were calculated using ANOVA or chi-square test where appropriate. Abbreviations: SD: standard 
deviation, n: number, TSH: thyrotropin, fT4: free thyroxine, fT3: triiodothyronine, TIA: transient ischemic attack. 
  
Figure 1. Association of quartiles of TSH, fT4 and fT3 with 10-year mortality risk by sex 
 
Bars represent hazard ratios (95% confidence interval). The fourth TSH quartile, the first fT4 quartile and the 
fourth fT3 quartile were set as reference categories. The symbol * indicates a significant difference with the 
reference. P-values were computed using continuous TSH, fT4 and fT3. Analyses were adjusted for age, 
education, smoking, hypertension, diabetes mellitus, atrial fibrillation, CHD, claudication, heart failure, 
depression/anxiety, stroke/TIA, cancer, number of medications. Ranges for TSH quartiles are first: 0.24-1.02, 
second: 1.03-1.55, third: 1.56-2.16 and fourth: 2.17-3.98 mU/L. Ranges for fT4 quartiles are first: 8.1-10.6, 
  
second: 10.7-11.9, third: 12.0-13.5 and fourth: 13.6-18.0 ng/L. Ranges for fT3 quartiles are first: 2.00-2.54, 
second: 2.55-2.90, third: 2.91-3.29 and fourth: 3.30-4.64 pg/mL. Abbreviations: HR: hazard ratio, TSH: 
thyrotropin, fT4: free thyroxine, fT3: triiodothyronine. 
  
  
Figure 2. Association of TSH, fT4 and fT3 with 10-year mortality risk by sex 
 
Bars represent hazard ratios (95% confidence interval) for 10-year mortality risk for each 1 mU/L increase in 
TSH, 1 ng/L increase in fT4 and 1 pg/mL increase in fT3. Analyses were adjusted for age, education, smoking, 
hypertension, diabetes mellitus, atrial fibrillation, CHD, claudication, heart failure, depression/anxiety, 
stroke/TIA, cancer, number of medications. Abbreviations: HR: hazard ratio, TSH: thyrotropin, fT4: free 
thyroxine, fT3: triiodothyronine. 
 
 
  
  
Figure 3. Association between TSH and 10-year mortality risk by sex and age 
 
Bars represent hazard ratios (95% confidence interval). Analyses were adjusted for age, education, smoking, 
hypertension, diabetes mellitus, atrial fibrillation, CHD, claudication, heart failure, depression/anxiety, 
stroke/TIA, cancer, number of medications. P-values for age interaction were computed using TSH and age as 
continuous variables. Abbreviations: HR: hazard ratio, TSH: thyrotropin. 
  
  
Figure 4. Association between TSH categories and 10-year mortality risk by sex 
 
Bars represent hazard ratios (95% confidence interval). Analyses were adjusted for age, education, smoking, 
hypertension, diabetes mellitus, atrial fibrillation, CHD, claudication, heart failure, depression/anxiety, 
stroke/TIA, cancer, number of medications. Abbreviations: HR: hazard ratio, TSH: thyrotropin. The symbol * 
indicates a significant difference with the reference category. P-values were calculated for continuous TSH. 
 
  
  
Supplementary Figure 1. Association of quartiles of TSH with 5-year mortality risk by 
sex 
                                    Men                                                                 Women 
 
Bars represent hazard ratios (95% confidence interval). The fourth and the third TSH quartile were set as reference 
category for men and women, respectively. The symbol * indicates a significant difference with the reference. P-
values for linear and for quadratic association were computed using TSH and squared TSH as continuous 
measures, respectively. Analyses were adjusted for age, education, smoking, hypertension, diabetes mellitus, atrial 
fibrillation, CHD, claudication, heart failure, depression/anxiety, stroke/TIA, cancer, number of medications. 
Ranges for TSH quartiles are first: 0.24-1.02, second: 1.03-1.55, third: 1.56-2.16 and fourth: 2.17-3.98 mU/L. 
Abbreviations: HR: hazard ratio, TSH: thyrotropin. 
  
  
Supplementary Table 1. Association of TSH, fT4 and fT3 with mortality risk at different 
follow-ups 
 Men Women 
 HR [95% CI] p-value 
for linear 
p-value for 
quadratic 
HR [95% CI] p-value 
for linear 
p-value for 
quadratic 
TSH       
At 1-year 0.61 [0.35; 1.07] 0.086 0.695 0.77 [0.50; 1.18] 0.227 0.099 
At 5-year 0.74 [0.59; 0.93] 0.009 0.818 1.05 [0.87; 1.25] 0.630 0.009 
At 10-year 0.81 [0.68; 0.96] 0.013 0.977 1.09 [0.96; 1.23] 0.206 0.074 
fT4       
At 1-year 1.08 [0.85; 1.38] 0.508 0.100 1.03 [0.85; 1.24] 0.766 0.335 
At 5-year 1.12 [1.01; 1.24] 0.033 0.390 0.99 [0.91; 1.07] 0.775 0.622 
At 10-year 1.12 [1.03; 1.21] 0.008 0.521 0.99 [0.94; 1.04] 0.660 0.909 
fT3       
At 1-year 0.50 [0.14; 1.79] 0.287 0.600 0.45 [0.19; 1.09] 0.077 0.461 
At 5-year 0.62 [0.38; 1.00] 0.050 0.321 0.59 [0.41; 0.84] 0.004 0.930 
At 10-year 0.78 [0.55; 1.10] 0.151 0.931 0.78 [0.62; 0.99] 0.037 0.827 
Hazard ratios (95% confidence intervals) are for each 1 mU/L increase in TSH, 1 ng/L increase in fT4 and 1 
pg/mL increase in fT3. All analyses were adjusted for age, education, smoking, hypertension, diabetes mellitus, 
atrial fibrillation, CHD, claudication, heart failure, depression/anxiety, stroke/TIA, cancer, number of 
medications. P-values for linear and quadratic associations were calculated using TSH, fT4 and fT3 as continuous 
variables in Cox-regression. Abbreviations: HR: hazard ratio, CI: confidence interval, TSH: thyrotropin, fT4: free 
thyroxine, fT3: triiodothyronine. 
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ABSTRACT 
Background: Heart rate and heart rate variability, markers of cardiac autonomic function, have 
been  related to cardiovascular diseases (CVD). We investigated whether heart rate and heart 
rate variability are associated with functional status in older subjects, independent of CVD. 
Methods: 5042 participants, mean age 75.3 years, were enrolled in PROSPER (PROspective 
Study of Pravastatin in the Elderly at Risk). Heart rate and heart rate variability (SDNN) were 
derived from baseline 10-second electrocardiograms. Functional status in basic (ADL) and 
instrumental (IADL) activities of daily living was measured using Barthel and Lawton scales, 
at baseline and during follow-up. Mean follow-up was 3.2 years. 
Results: At baseline, higher heart rate was associated with worse ADL and IADL, while lower 
SDNN was related to worse IADL (all p-values <0.05). Participants in the highest tertile of 
heart rate (range 71-117 beats/minute) had 1.79-fold (95% confidence interval (CI) 1.45-2.22) 
and 1.35-fold (95% CI 1.12-1.63) higher risk of decline in ADL and IADL, respectively (p for 
trend <0.001 and 0.001, respectively). Participants in the lowest tertile of SDNN (range 1.70-
13.30 milliseconds) had 1.21-fold (95% CI 1.00-1.46) and 1.25-fold (95% CI 1.05-1.48) higher 
risk of decline in ADL and IADL, respectively (both p for trends <0.05). All associations were 
independent of sex, medications, cardiovascular risk factors and co-morbidities. 
Interpretation: Higher resting heart rate and lower heart rate variability are associated with 
worse functional status and with higher risk of future functional decline in older subjects 
independent of CVD. Cardiac autonomic function correlates with the development of 
functional decline. 
  
  
INTRODUCTION 
Elevated heart rate and reduced heart rate variability — the beat-to-beat variation in heart rate 
intervals — both reflect an altered balance of the autonomic nervous system tone characterized 
by increased sympathetic and/or decreased parasympathetic activity1-3. Sympathetic 
overactivity has been linked to a procoagulant state and also to risk factors for atherosclerosis, 
including metabolic syndrome, obesity and subclinical inflammation2-4. Moreover, increased 
heart rate is related to atherosclerosis, not only as an epiphenomenon of sympathetic 
overactivity, but also through hemodynamic mechanisms, such as high pulsatile shear stress, 
which leads to endothelial dysfunction5. 
Atherosclerosis has been linked to increased risk of functional decline in older people via 
cardiovascular events6. As the world population is aging, the burden of functional disability is 
expected to increase6. It has been hypothesized that heart rate and heart rate variability are 
markers of frailty, an increased vulnerability to stressors and functional decline7. However, the 
direct link between these two parameters and risk of functional decline has not been fully 
established, and it is uncertain whether this association is independent of cardiovascular 
comorbidities. 
In this study, we examined whether heart rate and heart rate variability were cross-sectionally 
and longitudinally associated with functional status in older adults at high risk of cardiovascular 
disease, independent of cardiovascular risk factors and comorbidities. 
 
METHODS 
Study design and participants 
The data in this study were obtained from the Prospective Study of Pravastatin in the Elderly 
at Risk (PROSPER), a randomized controlled trial on the effect of pravastatin in a cohort of 
older men and women (70–82 yr) with pre-existing vascular disease or risk factors thereof. A 
total of 5804 individuals were recruited from 3 collaborating centres in Ireland, Scotland and 
the Netherlands. Details of study design, population recruitment and characteristics have been 
previously reported8,9. Exclusion criteria included physical or mental inability to attend clinic 
visits, poor cognitive function at baseline (Mini Mental State Examination score < 24), 
  
advanced heart failure (New York Heart Association functional class III or IV), 
electrocardiographic (ECG) evidence of atrial fibrillation or other major arrhythmias and 
implanted cardiac pacemakers. Participants were followed up for a mean of 3.2 years. 
From the original population, we excluded 150 participants with missing heart rate and/or heart 
rate variability measurements at baseline, 489 participants with cardiac rhythm not generated 
by sinoatrial node and 123 participants with missing data on functional status at baseline or 
during follow-up. We included participants from both the pravastatin and placebo arms because 
the PROSPER study group had previously shown that pravastatin did not affect functional 
status during follow-up9. Hence, 5042 participants were included in the present study. 
The PROSPER study complied with the Declaration of Helsinki and was approved by the 
medical ethics committees of the 3 centres. All participants provided written informed consent. 
 
Measurement of heart rate and heart rate variability 
We measured resting heart rate and heart rate variability from a 10-second, 12-lead ECG, 
recorded in the morning of the first enrolment visit to limit circadian variability. All ECGs 
were transmitted electronically for storage at the University of Glasgow ECG Core Laboratory 
based at Glasgow Royal Infirmary, Scotland, and interpreted using the same software10. 
We computed the standard deviation of normal-to- normal RR intervals (SDNN), one of the 
most frequently used and easily calculated indices of heart rate variability, by deriving it from 
normal-to-normal RR intervals11. Normal-to-normal RR intervals were defined as the time 
between two successive normally conducted QRS complexes. 
 
Functional status 
Functional status was assessed using two questionnaires: the Barthel Index12 and the Lawton 
Instrumental Activities of Daily Living Scale (IADL)13. The Barthel Index measures 
performance in basic activities of daily living (ADL) and consists of 10 items: fecal continence, 
urinary continence, grooming, toilet use, feeding, transfers (e.g., from chair to bed), walking, 
dressing, climbing stairs and bathing. The Lawton IADL evaluates more complex instrumental 
activities and includes 7 items: doing housework, taking medication as prescribed, managing 
  
money, shopping, using a phone or other forms of communication, using technology and taking 
transportation within the community. Scores for ADLs and IADLs range from 0 to 20 and from 
0 to 14, respectively, with higher scores indicating higher independence and better functional 
status. Functional status using the 2 questionnaires was measured at baseline; after 9, 18 and 
30 months; and at the end of the study, which varied between 36 and 42 months. Based on 
changes in functional status scores during follow-up, participants were classified as either 
declining or not declining in ADL and IADL. 
 
Statistical analysis 
We used SPSS version 20 for all the analyses. We reported baseline characteristics of 
participants as number of participants (percentage) for categorical variables and as mean 
(standard deviation) for continuous variables. We tested differences in baseline characteristics 
first across heart rate tertiles and then across SDNN tertiles, using analysis of variance for 
continuous variables and χ2 test for categorical variables. 
Linear regression analyses tested the cross-sectional associations of heart rate and SDNN with 
functional status. Dependent variables were the scores on each of the 2 functional status tests. 
We computed p values for trend using tertiles of heart rate and SDNN. 
We performed binary logistic regression analyses to investigate longitudinal associations of 
heart rate and SDNN with risk of decline in functional status. Independent variables were heart 
rate and SDNN. The outcome variable was the risk of declining in each of the functional status 
tests. We calculated odds ratios (ORs) and 95% confidence intervals (CIs) in tertiles of heart 
rate and SDNN, respectively. The reference categories were the lowest tertile of heart rate and 
the highest tertile of SDNN. We calculated p values for trend using tertiles of heart rate and 
SDNN. 
We performed all cross-sectional and longitudinal analyses in two steps. In the first step, 
analyses were adjusted for age, sex, country of enrolment and education (minimally adjusted 
model). In the second step, we further adjusted for cardiovascular risk factors (smoking status, 
body mass index [BMI], history of hypertension, history of diabetes mellitus), cardiovascular 
morbidities (history of myocardial infarction, history of stroke or transient ischemic attack, 
history of claudication), use of medications (diuretics, angiotensin-converting enzyme 
  
inhibitors, angiotensin receptor blockers, β-blockers, calcium channel blockers, nitrates, 
acetylsalicylic acid, anticoagulants) and statin treatment group. In the longitudinal analyses we 
also adjusted for baseline functional status (fully adjusted model). 
To test whether the association of heart rate and SDNN with functional status is independent 
of β-blocker use, we repeated the longitudinal analyses after exclusion of participants taking 
β-blockers. Furthermore, we repeated the longitudinal analyses after stratifying the participants 
by sex, history of hypertension, history of vascular diseases, use of β-blockers, calcium channel 
blockers or statin treatment to explore the potential modifying effect of these covariates. We 
computed interaction terms by multiplying heart rate and SDNN, as continuous variables, per 
these covariates. 
To explore the influence of vascular events on the longitudinal associations, we performed 
sensitivity analyses from which we excluded the following: 1) participants with incident stroke, 
2) participants with incident coronary events and 3) participants who were admitted to hospital 
for heart failure during follow-up. Furthermore, to check whether the longitudinal associations 
are affected by baseline functional status or by duration of follow-up, we performed sensitivity 
analyses including only 1) participants with maximum functional status at baseline and 2) 
participants who completed 36 months of follow-up. 
To check whether the association between SDNN and functional status is independent of heart 
rate, we repeated the analyses after standardizing SDNN for heart rate (dividing SDNN by 
heart rate)14. 
Finally, we repeated the longitudinal analyses by dividing the participants in the lowest tertile 
of heart rate into two groups of participants with a heart rate of less than 50 beats/min and 
participants with a heart rate of 50–60 beats/min. 
 
RESULTS 
The mean age of the study population was 75.3 years. A total of 2619 (51.9%) participants 
were female (Table 1). The median resting heart rate and SDNN were 65 beats/min and 18.6 
ms, respectively. Participants with a higher resting heart rate were older, were more likely to 
be female and current smokers, and had a higher BMI and a higher prevalence of diabetes 
  
mellitus. In contrast, participants with a lower resting heart rate used β-blockers more 
frequently and had a higher prevalence of myocardial infarction (all p values < 0.05) 
(Supplementary Table 1). Participants with lower heart rate variability as measured by SDNN 
had a higher BMI, a higher prevalence of diabetes mellitus and less frequently used β-blockers 
(all p values < 0.05) (Supplementary Table 2). 
Table 2 shows the associations of resting heart rate and SDNN with functional status at 
baseline. In the minimally adjusted model, participants with a higher resting heart rate had a 
worse performance in both functional status scales (p for trend < 0.05, for both). These 
associations remained significant in the fully adjusted model (p for trend < 0.05, for both). 
Likewise, participants with lower SDNN had a worse performance in both functional status 
scales in the minimally adjusted model (p for trend < 0.05, for both). After full adjustment, the 
same association persisted between SDNN and IADL (p for trend = 0.03). The same trend was 
observed between SDNN and ADL, although it did not reach significance (p for trend = 0.11). 
During a mean follow-up of 3.2 years, 779 participants (15.5%) declined in ADL score and 
1128 participants (22.4%) declined in IADL score. Among the participants who declined in 
ADL score, 406 (52.1%) declined 1 point, 141 (18.1%) 2 points and 232 (29.8%) 3 or more 
points. Among the participants who declined in IADL score, 402 (35.6%) declined 1 point, 224 
(19.9%) 2 points and 502 (44.5%) 3 or more points. 
Figure 1 shows the longitudinal associations of resting heart rate and SDNN with risk of decline 
in functional status after full adjustment. Participants with a resting heart rate in the highest 
tertile had a 1.79-fold (95% CI 1.45–2.22) and a 1.35-fold (95% CI 1.12–1.63) higher risk of 
decline in ADL and IADL scores, respectively (p for trend < 0.001 and 0.001, respectively). 
Participants with SDNN in the lowest tertile had 1.21-fold (95% CI 1.00–1.46) and 1.25-fold 
(95% CI 1.05–1.48) higher risk of decline in ADL and IADL scores, respectively (p for trend 
< 0.05, for both groups). These associations were similar in the minimally adjusted model (p 
for trend < 0.05, for all groups) (Supplementary Table 3). 
Table 3 shows the sensitivity analyses after exclusion of the 1320 participants receiving 
treatment with β-blockers. Higher resting heart rate and lower SDNN remained significantly 
related to a higher risk of decline for both ADL and IADL in the fully adjusted model (p for 
trend < 0.05, for all groups). To clarify whether cardiovascular events during follow-up might 
affect the longitudinal associations between resting heart rate/SDNN and risk of decline in 
  
functional status, we performed a series of sensitivity analyses after exclusion of 1) participants 
with incident stroke during follow-up (n = 220); 2) participants with incident coronary events 
during follow-up (n = 541); and 3) participants who were admitted to hospital for heart failure 
during follow-up (n = 196). Results did not materially change (Supplementary Table 4, 5 and 
6). 
To explore whether poor functional status at baseline might affect the longitudinal relation 
between resting heart rate/SDNN and risk of decline in functional status, we performed further 
sensitivity analyses including only participants with maximum functional status scores at 
baseline (n = 4343 participants with maximum ADL score, n = 4129 participants with 
maximum IADL score). Results did not materially change (Supplementary Table 7). 
To test whether short duration of follow-up might affect the results, we repeated the 
longitudinal analyses including only participants who completed 36 months of follow-up (n = 
4552). The longitudinal associations between resting heart rate/SDNN and risk of decline in 
functional status remained significant (Supplementary Table 8). 
The associations of resting heart rate and SDNN with functional decline were not modified by 
sex, history of hypertension or vascular diseases, use of β-blockers, calcium channel blockers 
or statin treatment (p for interaction > 0.05, for all groups) (Supplementary Figure 1 for heart 
rate; data not shown for SDNN). In an extra analysis, we tested whether the observed 
associations were independent of baseline cognitive function as assessed by the Mini Mental 
State Examination. The associations did not materially change after adjustment for baseline 
cognitive function (data not shown). Likewise, these associations remained unchanged when 
we standardized SDNN for heart rate (Supplementary Table 9 and 10). Furthermore, we 
observed no difference in risk of functional decline between participants with a heart rate of 
less than 50 beats/min (n = 284) and those with a heart rate of 50–60 beats/min (n = 1365). 
Participants in the highest tertile had a higher risk of functional decline compared with the 
participants in the group with a heart rate of 50–60 beats/min (Supplementary Table 11). 
 
 
 
  
INTERPRETATION 
 
In our study, higher resting heart rate and lower heart rate variability were associated with 
worse functional performance at baseline and with higher risk of future functional decline in 
older adults at high cardiovascular risk. These associations were independent of cardiovascular 
risk factors, cardiovascular morbidities and use of medications. 
The results of our study are in line with the results of the Prevention Regimen for Effectively 
Avoiding Second Stroke (PRoFESS) trial, which showed that higher heart rate was related to 
worse functional outcomes in patients with a recurrent stroke15. Our results are also consistent 
with findings from the Women’s Health and Aging Study-I (WHAS-I), which showed a cross-
sectional association between lower heart rate variability and frailty in disabled older women 
living in the community16. Our study extends the findings of WHAS-I to older adults at risk 
for cardiovascular disease with preserved functional status. Furthermore, we showed that the 
association of heart rate variability with functional decline was independent of sex. 
Different pathophysiological mechanisms may underlie these associations. First, higher heart 
rate and lower heart rate variability have been consistently associated with incident 
cardiovascular events in previous studies1-3. In this study, the strength of the associations 
between heart rate/heart rate variability and functional decline did not materially change after 
exclusion of participants with incident cardiovascular events. This might suggest that 
mechanisms other than macrovascular damage play roles in the association between heart 
rate/heart rate variability and functional decline. Second, lower heart rate is associated with 
better cardiovascular fitness, which is a protective factor for brain aging and functional 
decline17. In particular, lower heart rate is related to less myocardial oxygen consumption and 
more prolonged time available for diastolic heart chamber filling and coronary perfusion18. 
Furthermore, higher heart rate has been suggested to increase pulsatile shear stress, which leads 
to endothelial dysfunction and accelerated atherosclerosis5,19. In this setting, use of ivabradine, 
a pure heart rate-lowering agent, in relation to cardiovascular outcomes has been tested with 
conflicting results20-22. Third, heart rate and heart rate variability reflect the autonomic nervous 
system’s control over cardiac function. Cardiac autonomic control regulates the interaction 
between circulation and respiration. Higher heart rate variability in synchrony with respiration 
improves the efficiency of gas exchange at the level of the lung via efficient ventilation and 
  
perfusion matching23. Furthermore, cardiac autonomic control keeps blood pressure constant 
within a certain range to maintain adequate perfusion to vital organs, including the brain. A 
preserved cardiac autonomic control buffers variations in blood pressure in response to 
stressors. Indeed, participants with lower heart rate variability present higher blood pressure 
variability in response to psychological challenge or tilt test24,25. Higher blood pressure 
variability is associated with atherosclerosis26 and silent brain damage27. Finally, the autonomic 
nervous system is connected to regions of the central nervous system28,29, which are involved 
in mood regulation. Lower heart rate variability has been associated with depression30,31, which 
is a cause of disability6. 
 
Strengths and limitations 
A strength of our study was the longitudinal design, which allowed us to show that high heart 
rate and low heart rate variability preceded the decline in functional status. We also showed 
that this association was independent of potential confounders such as vascular diseases and 
use of antihypertensive and cardioprotective medications. However, causality cannot be 
inferred given the observational nature of this study. Further strengths are the large study 
population of older adults and the multicentre design. 
A limitation of our study was that all participants were older adults at high cardiovascular risk, 
which may limit the generalizability of our findings. Nevertheless, a considerable number of 
older adults carry high loads of cardiovascular pathologies and comorbidities. Moreover, we 
categorized our participants into the clinically distinguishable groups of those who declined 
and those who did not decline, although this categorization may result in loss of information. 
Another possible limitation is the use of a 10-second ECG; nonetheless, we were able to show 
a significant association of resting heart rate and heart rate variability with functional status 
even by using a short ECG recording, which is more feasible in clinical practice than longer 
recordings. Heart rate variability measured from standard 10-second ECG recordings correlates 
with heart rate variability measured from longer ECG recordings11. 
 
 
  
Conclusion 
We found that higher resting heart rate and lower heart rate variability were associated with 
worse functional status in older adults, independent of cardiovascular risk factors and 
comorbidities. This study provides insight into the role of cardiac autonomic function in the 
development of functional decline. Because functional disability has a long preclinical phase, 
it is crucial to identify potential interventions to delay it. Further research is needed to establish 
whether heart rate and heart rate variability are risk markers and/or potentially modifiable risk 
factors for functional decline. Pharmacologic and nonpharmacologic interventions (e.g., drugs 
with antiadrenergic properties, physical exercise, nervus vagus stimulation) aimed at 
modulating cardiac autonomic function may be beneficial in preserving functional status. It is 
well established that physical activity is a key contributor in autonomic regulation and is linked 
with preservation of functional status32,33. However, future studies are needed to test the 
influence of physical activity on functionality through autonomic regulation in older adults. 
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Table 1. Characteristics of the study population at baseline 
 
Characteristic 
 
No. (%) of participants* 
Socio-demographics  
   Age, years, mean ± SD 75.3 ± 3.3 
   Female sex 2619 (51.9) 
   Age left school, years, mean ± SD 15.1 ± 2.1 
Cardiovascular risk factors  
   History of hypertension 3127 (62.0) 
   History of stroke or TIA 552 (10.9) 
   History of MI 662 (13.1) 
   History of claudication 336 (6.7) 
   History of diabetes mellitus 517 (10.3) 
   Current smoking 1334 (26.5) 
   BMI, kg/m 2 , mean ± SD 26.8 ± 4.2 
Medications  
   Beta-blockers 1320 (26.2) 
   Calcium channel blockers 1275 (25.3) 
   Statins 2504 (49.7) 
Abbreviations: HR: Heart Rate; SD: Standard Deviation; TIA: Transient Ischemic Attack; MI: Myocardial 
Infarction; BMI: Body Mass Index. *Unless stated otherwise. 
  
  
Table 2. Baseline functional status in tertiles of resting heart rate and SDNN 
 Tertiles of HR/SDNN  
 Low Middle High P for trend 
Heart Rate n=1649 n=1742 n=1651  
HR range, beats/min 34-60 61-70 71-117  
ADL score     
   Model 1 19.79 (0.02) 19.78 (0.02) 19.71 (0.02) 0.004 
   Model 2 19.27 (0.25) 19.26 (0.25) 19.21 (0.25) 0.02 
IADL score     
   Model 1 13.67 (0.03) 13.62 (0.02) 13.52 (0.03) <0.001 
   Model 2 12.94  (0.34) 12.89 (0.34) 12.80 (0.33) <0.001 
SDNN n=1689 n=1670 n=1683  
SDNN range, ms 1.70-13.30 13.40-26.50 26.60-422.60  
ADL score     
   Model 1 19.73 (0.02) 19.75 (0.02) 19.80 (0.02) 0.01 
   Model 2 19.23 (0.25) 19.24 (0.25) 19.27 (0.25) 0.11 
IADL score     
   Model 1 13.55 (0.03) 13.62 (0.03) 13.65 (0.02) 0.004 
   Model 2 12.84 (0.33) 12.90 (0.34) 12.91 (0.34) 0.03 
ADL and IADL scores are presented as means (standard errors). Abbreviations: HR: Heart Rate; SDNN: Standard 
Deviation of the Normal to Normal R-R intervals; n: Number; beats/min: beats/minute; ms: milliseconds; ADL: 
basic Activities of Daily Living; IADL: Instrumental Activities of Daily Living. Model 1: adjusted for country, 
age, sex, education. Model 2: adjusted for country, age, sex, education, smoking, body mass index, history of 
hypertension, history of diabetes mellitus, history of claudication, history of myocardial infarction, history of 
stroke/transient ischemic attack, statin treatment, diuretics, angiotensin converting enzyme inhibitors, angiotensin 
receptor blockers, beta-blockers, calcium-channel blockers, nitrates, aspirin and anticoagulants.  
  
  
Table 3. Risk of decline in functional status in tertiles of resting heart rate and SDNN 
after exclusion of participants taking beta-blockers  
 Tertiles of HR/SDNN  
 Low Middle High P for trend 
Heart Rate n=863 n=1379 n=1480  
ADL, OR (95% CI)     
   Model 1 1 (ref) 1.27 [0.97;1.67] 1.95 [1.50;2.53] <0.001 
   Model 2 1 (ref) 1.25 [0.95;1.65] 1.86 [1.43;2.42] <0.001 
IADL, OR (95% CI)     
   Model 1 1 (ref) 1.09 [0.87;1.37] 1.46 [1.17;1.81] <0.001 
   Model 2 1 (ref) 1.07 [0.85;1.35] 1.39 [1.11;1.74] 0.002 
SDNN n=1312 n=1192 n=1218  
ADL, OR (95% CI)     
   Model 1 1.31 [1.06;1.63] 0.85 [0.67;1.08] 1 (ref) 0.009 
   Model 2 1.25 [1.00;1.55] 0.82 [0.65;1.04] 1 (ref) 0.03 
IADL, OR (95% CI)     
   Model 1 1.30 [1.07;1.58] 1.09 [0.89;1.34] 1 (ref) 0.008 
   Model 2 1.26 [1.03;1.53] 1.07 [0.87;1.31] 1 (ref) 0.02 
Abbreviations: HR: Heart Rate; SDNN: Standard Deviation of the Normal to Normal R-R intervals; n: Number; 
msec: milliseconds; ADL: basic Activities of Daily Living; IADL: Instrumental Activities of Daily Living; OR: 
Odds Ratio; CI: Confidence Interval.  Model 1: adjusted for country, age, sex, education. Model 2: adjusted for 
country, age, sex, education, ADL/IADL at baseline, smoking, body mass index, history of hypertension, history 
of diabetes mellitus, history of claudication, history of myocardial infarction, history of stroke/transient ischemic 
attack, statin treatment, diuretics, angiotensin converting enzyme inhibitors, angiotensin receptor blockers, 
calcium-channel blockers, nitrates, aspirin and anticoagulants. 
  
  
Figure 1. Risk of decline in functional status in tertiles of resting heart rate and SDNN 
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Bars represent odds ratios with 95% confidence intervals. All analyses are adjusted for country, age, sex, 
education, ADL/IADL at baseline, smoking, body mass index, history of hypertension, history of diabetes 
mellitus, history of claudication, history of myocardial infarction, history of stroke/transient ischemic attack, statin 
treatment, diuretics, angiotensin converting enzyme inhibitors, angiotensin receptor blockers, beta-blockers, 
calcium-channel blockers, nitrates, aspirin and anticoagulants. Range of heart rate (number of participants) in 
heart rate tertiles: low 34-60 beats/minute (n=1649); middle 61-70 beats/minute (n=1742); high 71-117 
beats/minute (n=1651). Range of SDNN (number of participants) in SDNN tertiles: low 1.70-13.30 msec 
(n=1689); middle 13.40-26.50 msec (n=1670); high 26.60-422.60 msec (n=1683). Abbreviations: ADL: basic 
Activities of Daily Living; IADL: Instrumental Activities of Daily Living; OR: Odds Ratios; CI: Confidence 
Interval; SDNN: Standard Deviation of the Normal to Normal R-R intervals. 
  
Supplementary Table 1. Characteristics of study population in tertiles of resting heart 
rate 
 Tertiles of HR (beats/minute)  
Characteristics 
Low 
(34-60) 
n=1649 
Middle 
(61-70) 
n=1742 
High 
(71-117) 
n=1651 
p-value 
Heart rate, beats/minute, mean (SD) 54.3 (4.7) 65.3 (2.8) 79.3 (7.6)  
Socio-demographics     
Age, years, mean (SD) 75.1 (3.3) 75.3 (3.3) 75.4 (3.4) 0.01 
Female, n (%) 706 (42.8) 928 (53.3) 985 (59.7) <0.001 
Age left school, years, mean (SD) 15.2 (2.1) 15.2 (2.1) 15.1 (1.9) 0.37 
Cardiovascular risk factors     
History of hypertension, n (%) 1046 (63.4) 1056 (60.6) 1025 (62.1) 0.24 
History of stroke or TIA, n (%) 184 (11.2) 187 (10.7) 181 (11.0) 0.93 
History of MI, n (%) 273 (16.6) 189 (10.8) 200 (12.1) <0.001 
History of claudication, n (%) 94 (5.7) 124 (7.1) 118 (7.1) 0.16 
History of diabetes mellitus, n (%) 115 (7.0) 180 (10.3) 222 (13.4) <0.001 
Current smoking, n (%) 361 (21.9) 499 (28.6) 474 (28.7) <0.001 
BMI, kg/m 2 , mean (SD) 26.8 (3.9) 26.7 (4.1) 27.1 (4.5) 0.02 
Medications     
Beta-blockers, n (%) 786 (47.7) 363 (20.8) 171 (10.4) <0.001 
Calcium channel blockers, n (%)  432 (26.2) 415 (23.8) 428 (25.9) 0.22 
Statins, n (%) 843 (51.1) 867 (49.8) 794 (48.1) 0.22 
Abbreviations: HR: Heart Rate; SD: Standard Deviation; n: Number; TIA: Transient Ischemic Attack; MI: 
Myocardial Infarction; BMI: Body Mass Index. 
  
  
Supplementary Table 2. Characteristics of study population in tertiles of SDNN 
 Tertiles of SDNN (msec)  
Characteristics Low 
(1.70-
13.30) 
n=1689 
Medium 
(13.40-
26.50) 
n=1670 
High 
(26.60-
422.60) 
n=1683 
p-
value 
 
Socio-demographics     
Age, years, mean (SD) 75.36 (3.39) 75.12 (3.30) 75.32 (3.32) 0.08 
Female, n (%) 879 (52.0) 907 (54.3) 833 (49.5) 0.02 
Age left school, years, mean (SD) 15.16 (2.00) 15.17 (2.08) 15.10 (2.08) 0.59 
Cardiovascular factors: 
History of hypertension, n (%) 1079 (63.9) 1028 (61.6) 1020 (60.6) 0.13 
History of stroke or TIA, n (%) 202 (12.0) 188 (11.3) 162 (9.6) 0.08 
History of MI, n (%) 220 (13.0) 212 (12.7) 230 (13.7) 0.61 
History of claudication, n (%) 129 (7.4) 113 (6.8) 94 (5.6) 0.06 
History of diabetes mellitus, n 
(%) 
210 (12.4) 160 (9.2) 147 (8.7) 0.001 
Current smoking, n (%) 423 (25.0) 452 (27.1) 459 (27.3) 0.27 
BMI, kg/m 2  mean (SD) 27.12 (4.25) 26.78 (4.13) 26.64 (4.12) 0.003 
Medications:     
Beta-blockers, n (%) 377 (22.3) 478 (28.6) 465 (27.6) <0.001 
Calcium channel blockers, n (%) 424 (25.1) 424 (25.4) 427 (25.4) 0.98 
Statins, n (%)  846 (50.1) 811 (48.6) 847 (50.3) 0.54 
Abbreviations: SD: standard deviation; n: Number; TIA: Transient Ischemic Attack; MI: Myocardial Infarction; 
BMI: Body Mass Index. 
 
  
  
Supplementary Table 3. Risk of decline in functional status in tertiles of resting heart rate 
and SDNN in the minimally adjusted models 
 Tertiles of HR/SDNN  
 Low Middle High P for trend 
Heart Rate n=1649 n=1742 n=1651  
HR range, beats/min 34-60 61-70 71-117  
ADL, OR (95% CI) 
   Model 1 1 (ref) 1.16 [0.95;1.42] 1.70 [1.40;2.06] <0.001 
IADL, OR (95% CI) 
   Model 1 1 (ref) 1.06 [0.90;1.27] 1.37 [1.15;1.63] <0.001 
SDNN n=1689 n=1670 n=1683  
SDNN range, ms 1.70-13.30 13.40-26.50 26.60-422.60  
ADL, OR (95% CI) 
   Model 1 1.28 [1.06;1.54] 0.88 [0.72;1.07] 1 (ref) 0.008 
IADL, OR (95% CI) 
   Model 1 1.30 [1.10;1.53] 1.11 [0.94;1.32] 1 (ref) 0.003 
Abbreviations: HR: Heart Rate; SDNN: Standard Deviation of the Normal to Normal R-R intervals; n: Number; 
msec: milliseconds; ADL: basic Activities of Daily Living; IADL: Instrumental Activities of Daily Living; OR: 
Odds Ratio; CI: Confidence Interval. Model 1: adjusted for country, age, sex and education. 
  
  
Supplementary Table 4. Risk of decline in functional status in tertiles of resting heart rate 
and SDNN after exclusion of participants with incident non-fatal stroke during follow-up 
 Tertiles of HR/SDNN  
 Low Middle High P for trend 
Heart Rate n=1580 n=1685 n=1577  
ADL, OR (95% CI)     
   Model 1 1 (ref) 1.16 [0.94;1.44] 1.74 [1.41;2.13] <0.001 
   Model 2 1 (ref) 1.24 [0.99;1.55] 1.84 [1.47;2.30] <0.001 
IADL, OR (95% CI)     
   Model 1 1 (ref) 1.08 [0.90;1.29] 1.41 [1.17;1.68] <0.001 
   Model 2 1 (ref) 1.07 [0.89;1.30] 1.37 [1.12;1.66] 0.001 
SDNN n=1626 n=1603 n=1613  
ADL, OR (95% CI)     
   Model 1 1.34 [1.11;1.63] 0.92 [0.75;1.13] 1 (ref) 0.002 
   Model 2 1.27 [1.04;1.55] 0.88 [0.72;1.09] 1 (ref) 0.02 
IADL, OR (95% CI)     
   Model 1 1.35 [1.13;1.61] 1.14 [0.95;1.36] 1 (ref) 0.001 
   Model 2 1.29 [1.08;1.54] 1.11 [0.93;1.33] 1 (ref) 0.005 
Abbreviations: HR: Heart Rate; SDNN: Standard Deviation of the Normal to Normal R-R intervals; n: Number; 
msec: milliseconds; ADL: basic Activities of Daily Living; IADL: Instrumental Activities of Daily Living; OR: 
Odds Ratio; CI: Confidence Interval. Model 1: adjusted for country, age, sex, education. Model 2: adjusted for 
country, age, sex, education, ADL/IADL at baseline, smoking, body mass index, history of hypertension, history 
of diabetes mellitus, history of claudication, history of myocardial infarction, history of stroke/transient ischemic 
attack, statin treatment, diuretics, angiotensin converting enzyme inhibitors, angiotensin receptor blockers, beta-
blockers, calcium-channel blockers, nitrates, aspirin and anticoagulants. 
  
  
Supplementary Table 5. Risk of decline in functional status in tertiles of resting heart rate 
and SDNN after exclusion of participants with incident coronary events during follow-up 
 Tertiles of HR/SDNN  
 Low Middle High P for trend 
Heart Rate n=1459 n=1564 n=1478  
ADL, OR (95% CI)     
   Model 1 1 (ref) 1.06 [0.85;1.31] 1.58 [1.28;1.95] <0.001 
   Model 2 1 (ref) 1.13 [0.90;1.42] 1.69 [1.34;2.12] <0.001 
IADL, OR (95% CI)     
   Model 1 1 (ref) 0.97 [0.81;1.17] 1.31 [1.09;1.57] 0.003 
   Model 2 1 (ref) 0.97 [0.80;1.18] 1.27 [1.04;1.55] 0.02 
SDNN n=1489 n=1507 n=1505  
ADL, OR (95% CI)     
   Model 1 1.33 [1.09;1.63] 0.89 [0.71;1.08] 1 (ref) 0.004 
   Model 2 1.27 [1.04;1.55] 0.85 [0.68;1.05] 1 (ref) 0.02 
IADL, OR (95% CI)     
   Model 1 1.31 [1.10;1.57] 1.10 [0.91;1.32] 1 (ref) 0.003 
   Model 2 1.27 [1.06;1.53] 1.08 [0.90;1.30] 1 (ref) 0.01 
Abbreviations: HR: Heart Rate; SDNN: Standard Deviation of the Normal to Normal R-R intervals; n: Number; 
msec: milliseconds; ADL: basic Activities of Daily Living; IADL: Instrumental Activities of Daily Living; OR: 
Odds Ratio; CI: Confidence Interval. Model 1: adjusted for country, age, sex, education. Model 2: adjusted for 
country, age, sex, education, ADL/IADL at baseline, smoking, body mass index, history of hypertension, history 
of diabetes mellitus, history of claudication, history of myocardial infarction, history of stroke/transient ischemic 
attack, statin treatment, diuretics, angiotensin converting enzyme inhibitors, angiotensin receptor blockers, beta-
blockers, calcium-channel blockers, nitrates, aspirin and anticoagulants. 
 
  
  
Supplementary Table 6. Risk of decline in functional status in tertiles of resting heart rate 
and SDNN after exclusion of participants with incident heart failure hospitalization 
during follow-up 
 Tertiles of HR/SDNN  
 Low Middle High P for trend 
Heart Rate n=1599 n=1672 n=1575  
ADL, OR (95% CI)     
   Model 1 1 (ref) 1.12 [0.91;1.37] 1.63 [1.33;1.99] <0.001 
   Model 2 1 (ref) 1.18 [0.95;1.47] 1.72 [1.38;2.14] <0.001 
IADL, OR (95% CI)     
   Model 1 1 (ref) 1.00 [0.84;1.19] 1.30 [1.09;1.55] 0.003 
   Model 2 1 (ref) 1.00 [0.83;1.20] 1.27 [1.05;1.54] 0.01 
SDNN n=1606 n=1620 n=1620  
ADL, OR (95% CI)     
   Model 1 1.33 [1.10;1.61] 0.89 [0.73;1.10] 1 (ref) 0.003 
   Model 2 1.27 [1.04;1.54] 0.87 [0.70;1.06] 1 (ref) 0.02 
IADL, OR (95% CI)     
   Model 1 1.30 [1.09;1.55] 1.15 [0.96;1.37] 1 (ref) 0.003 
   Model 2 1.25 [1.05;1.50] 1.13 [0.94;1.35] 1 (ref) 0.01 
Abbreviations: HR: Heart Rate; SDNN: Standard Deviation of the Normal to Normal R-R intervals; n: Number; 
msec: milliseconds; ADL: basic Activities of Daily Living; IADL: Instrumental Activities of Daily Living; OR: 
Odds Ratio; CI: Confidence Interval. Model 1: adjusted for country, age, sex, education. Model 2: adjusted for 
country, age, sex, education, ADL/IADL at baseline, smoking, body mass index, history of hypertension, history 
of diabetes mellitus, history of claudication, history of myocardial infarction, history of stroke/transient ischemic 
attack, statin treatment, diuretics, angiotensin converting enzyme inhibitors, angiotensin receptor blockers, beta-
blockers, calcium-channel blockers, nitrates, aspirin and anticoagulants. 
 
  
  
Supplementary Table 7. Risk of decline in functional status in tertiles of resting heart rate 
and SDNN after inclusion of participants with maximum functional status at baseline 
 Tertiles of HR/SDNN  
 Low Middle High P for trend 
Heart Rate     
ADL, OR (95% CI) n=1465 n=1491 n=1387  
   Model 1 1 (ref) 1.25 [1.00;1.57] 1.75 [1.41;2.18] <0.001 
   Model 2 1 (ref) 1.34 [1.06;1.70] 1.88 [1.48;2.40] <0.001 
IADL, OR (95% CI) n=1397 n=1433 n=1299  
   Model 1 1 (ref) 1.14 [0.94;1.39] 1.35 [1.10;1.65] 0.003 
   Model 2 1 (ref) 1.19 [0.97;1.46] 1.42 [1.14;1.76] 0.002 
SDNN     
ADL, OR (95% CI) n=1441 n= 1428 n= 1474  
   Model 1 1.19 [0.97;1.46] 0.78 [0.63;0.98] 1 (ref) 0.09 
   Model 2 1.13 [0.92;1.40] 0.77 [0.61;0.96] 1 (ref) 0.23 
IADL, OR (95% CI) n=1350 n=1383 n=1396  
   Model 1 1.29 [1.06;1.56] 1.12 [0.92;1.36] 1 (ref) 0.01 
   Model 2 1.26 [1.03;1.53] 1.10 [0.90;1.34] 1 (ref) 0.02 
Abbreviations: HR: Heart Rate; SDNN: Standard Deviation of the Normal to Normal R-R intervals; n: Number; 
msec: milliseconds; ADL: basic Activities of Daily Living; IADL: Instrumental Activities of Daily Living; OR: 
Odds Ratio; CI: Confidence Interval. Model 1: adjusted for country, age, sex, education. Model 2: adjusted for 
country, age, sex, education, smoking, body mass index, history of hypertension, history of diabetes mellitus, 
history of claudication, history of myocardial infarction, history of stroke/transient ischemic attack, statin 
treatment, diuretics, angiotensin converting enzyme inhibitors, angiotensin receptor blockers, beta-blockers, 
calcium-channel blockers, nitrates, aspirin and anticoagulants. 
 
  
  
Supplementary Table 8. Risk of decline in functional status in tertiles of resting heart rate 
and SDNN after inclusion of participants who completed 36 months of follow-up 
 Tertiles of HR/SDNN  
 Low Middle High P for trend 
Heart Rate n=1513 n=1576 n=1463  
ADL, OR (95% CI)     
   Model 1 1 (ref) 1.15 [0.93;1.43] 1.72 [1.40;2.12] <0.001 
   Model 2 1 (ref) 1.23 [0.98;1.54] 1.86 [1.48;2.33] <0.001 
IADL, OR (95% CI)     
   Model 1 1 (ref) 1.04 [0.86;1.25] 1.30 [1.08;1.56] 0.005 
   Model 2 1 (ref) 1.06 [0.87;1.28] 1.30 [1.06;1.59] 0.009 
SDNN n=1491 n=1530 n=1531  
ADL, OR (95% CI)     
   Model 1 1.30 [1.07;1.58] 0.91 [0.74;1.12] 1 (ref) 0.008 
   Model 2 1.23 [1.01;1.50] 0.87 [0.71;1.08] 1 (ref) 0.04 
IADL, OR (95% CI)     
   Model 1 1.34 [1.12;1.61] 1.11 [0.93;1.34] 1 (ref) 0.001 
   Model 2 1.28 [1.07;1.54] 1.08 [0.90;1.30] 1 (ref) 0.008 
Abbreviations: HR: Heart Rate; SDNN: Standard Deviation of the Normal to Normal R-R intervals; n: Number; 
msec: milliseconds; ADL: basic Activities of Daily Living; IADL: Instrumental Activities of Daily Living; OR: 
Odds Ratio; CI: Confidence Interval. Model 1: adjusted for country, age, sex, education. Model 2: adjusted for 
country, age, sex, education, ADL/IADL at baseline, smoking, body mass index, history of hypertension, history 
of diabetes mellitus, history of claudication, history of myocardial infarction, history of stroke/transient ischemic 
attack, statin treatment, diuretics, angiotensin converting enzyme inhibitors, angiotensin receptor blockers, beta-
blockers, calcium-channel blockers, nitrates, aspirin and anticoagulants.  
  
  
Supplementary Figure 1. Risk of functional decline in relation to heart rate in stratified 
analyses 
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Bars represent odds ratios (95% confidence interval) per each standard deviation increase in resting heart rate in 
stratified analyses. Adjusted for country, age, sex, education, ADL/IADL at baseline, smoking, body mass index, 
history of hypertension, history of diabetes mellitus, history of claudication, history of myocardial infarction, 
history of stroke/transient ischemic attack, statin treatment, diuretics, angiotensin converting enzyme inhibitors, 
angiotensin receptor blockers, calcium-channel blockers, nitrates, aspirin and anticoagulants. P- values show p for 
interaction. Abbreviations: OR: odds ratio; CI: confidence interval; ADL: activities of daily living; IADL: 
instrumental activities of daily living. 
  
  
Supplementary Table 9. Baseline functional status in tertiles of standardized SDNN 
 Tertiles of standardized SDNN  
 Low 
n=1680 
Middle 
n=1681 
High 
n=1681 
P for trend 
SDNN range, ms 0.02-0.20 0.20-0.43 0.43-7.85  
 ADL score     
   Model 1 19.73 (0.02) 19.77 (0.02) 19.79 (0.02) 0.021 
   Model 2 19.22 (0.25) 19.25 (0.25) 19.26 (0.25) 0.180 
 IADL score     
   Model 1 13.54 (0.03) 13.60 (0.02) 13.66 (0.02) 0.001 
   Model 2 12.83 (0.33) 12.88 (0.34) 12.93 (0.34) 0.008 
ADL and IADL scores are presented as means (standard errors). Abbreviations: SDNN: Standard Deviation of 
the Normal to Normal R-R intervals; n: number; ms: milliseconds; ADL: basic Activities of Daily Living; IADL: 
Instrumental Activities of Daily Living. Model 1: adjusted for country, age, sex, education. Model 2: adjusted for 
country, age, sex, education, smoking, body mass index, history of hypertension, history of diabetes mellitus, 
history of claudication, history of myocardial infarction, history of stroke/transient ischemic attack, statin 
treatment, diuretics, Angiotensin Converting Enzyme inhibitors, angiotensin receptor blockers, beta-blockers, 
calcium-channel blockers, nitrates, aspirin, anticoagulants. 
  
  
Supplementary Table 10. Risk of decline in functional status in tertiles of standardized 
SDNN 
 Tertiles of standardized SDNN  
 Low 
n=1680 
Middle 
n=1681 
High 
n=1681 
P for trend 
SDNN range, ms 0.02-0.20 0.20-0.43 0.43-7.85  
ADL, OR (95% CI) 
   Model 1 1.32 [1.10;1.59] 0.98 [0.80;1.19] 1 (ref) 0.003 
   Model 2 1.26 [1.04;1.53] 0.94 [0.77;1.15] 1 (ref) 0.015 
 IADL, OR (95% CI) 
   Model 1 1.31 [1.11;1.55] 1.17 [0.99;1.39] 1 (ref) 0.002 
   Model 2 1.26 [1.06;1.49] 1.14 [0.96;1.35] 1 (ref) 0.010 
Abbreviations: SDNN: Standard Deviation of the Normal to Normal R-R intervals; n: number; ms: milliseconds; 
ADL: basic Activities of Daily Living; IADL: Instrumental Activities of Daily Living; OR: Odds Ratio; CI: 
Confidence Interval. Model 1: adjusted for country, age, sex, education. Model 2: adjusted for country, age, sex, 
education, ADL/IADL at baseline, smoking, body mass index, history of hypertension, history of diabetes 
mellitus, history of claudication, history of myocardial infarction, history of stroke/transient ischemic attack, statin 
treatment, diuretics, Angiotensin Converting Enzyme inhibitors, angiotensin receptor blockers, beta-blockers, 
calcium-channel blockers, nitrates, aspirin, anticoagulants. 
  
  
Supplementary Table 11. Risk of decline in functional status in groups of resting heart 
rate 
 Groups of HR (beats/minute)  
 < 50 
n = 284 
50-60 
n = 1365 
61-70 
n = 1742 
71-117 
n = 1651 
P for 
trend 
ADL, OR (95% CI) 0.76 [0.49;1.19] 1 (ref) 1.19 [0.95;1.48] 1.73 [1.39;2.15] 0.002 
IADL, OR (95% CI) 1.32 [0.95;1.84] 1 (ref) 1.12 [0.93;1.36] 1.41 [1.16;1.72] <0.001 
Abbreviations: HR: Heart Rate; n: Number; ADL: basic Activities of Daily Living; IADL: Instrumental Activities 
of Daily Living; OR: Odds Ratio; CI: Confidence Interval. Adjusted for country, age, sex, education, ADL/IADL 
at baseline, smoking, body mass index, history of hypertension, history of diabetes mellitus, history of 
claudication, history of myocardial infarction, history of stroke/transient ischemic attack, statin treatment, 
diuretics, angiotensin converting enzyme inhibitors, angiotensin receptor blockers, calcium-channel blockers, 
nitrates, aspirin and anticoagulants. 
  
  
 
 
 
 
 
 
 
 
 
Chapter 6 
Blood pressure variability and functional decline 
 
 
 
 
 
Manuscript based on this chapter has been submitted as: 
Ogliari G, Smit RA, Westendorp RG, Jukema JW, de Craen AJ, Sabayan B. Visit-to-visit blood 
pressure variability and future functional decline in old age. 
  
  
ABSTRACT 
Background: Higher blood pressure variability (BPV), independent of mean blood pressure, 
has been associated with adverse health outcomes. 
Objective: To determine the association between visit-to-visit BPV and functional decline in 
older adults at high cardiovascular risk. 
Design: Prospective cohort study. 
Setting: PROSPER (PROspective Study of Pravastatin in the Elderly at Risk) study. 
Participants: 4745 participants with mean age of 75.2 years and high cardiovascular risk were 
followed for a mean of 3.2 years. Blood pressure was measured every three months during the 
first 18 months. BPV was defined as the intra-individual standard deviation (SD) of 
measurements across these visits. 
Measurements: Functional status in basic and instrumental activities of daily living was 
measured using the Barthel (ADL) and Lawton (IADL) scales, at 18 months and during follow-
up. Functional decline between 18 months and the end of follow-up was calculated. 
Results: BPV was not associated with functional status at 18 months. Higher systolic BPV was 
associated with steeper functional decline, whereas diastolic BPV was not. Each 10 mmHg 
higher SD of SBP was associated with a 0.064 (95% CI 0.016-0.112, p = 0.009) annual decline 
in ADL score and with a 0.078 decline (95% CI 0.020-0.136, p = 0.008) in IADL score. These 
associations were not modified by sex, hypertension or use of antihypertensives. These findings 
were independent of mean blood pressure, cardiovascular risk factors and morbidities and 
cognition. 
Conclusion: Higher visit-to-visit systolic but not diastolic BPV was associated with steeper 
functional decline in older adults at high cardiovascular risk. Higher systolic BPV is a novel 
risk factor for functional decline. 
  
  
INTRODUCTION 
Visit-to-visit blood pressure variability (BPV) is the intra-individual variation in blood pressure 
measures over different clinical visits1. BPV is a reproducible phenomenon, with a possible 
genetic basis, and may be increased or decreased by antihypertensive drugs2-4. Higher visit-to-
visit BPV, independent of mean blood pressure, has been associated with clinical events, such 
as stroke, myocardial infarction, cardiovascular and all-cause mortality5,6. Furthermore, it has 
been associated with subclinical end-organ damage, including cerebral small vessel disease, 
cardiac diastolic dysfunction, micro- and macro-albuminuria7,8. All these associations may be 
mediated by vascular damage, as suggested by the link of BPV with endothelial injury, arterial 
stiffness and atherosclerosis7-10. 
Vascular damage is a determinant of functional decline in older adults11,12. With the rapid 
ageing of populations worldwide, it is crucial to identify potential etiologic factors underlying 
vascular damage and functional decline. Although evidence shows the association between 
BPV and vascular damage, the relationship between BPV and functional decline has not been 
explored. 
Therefore, we investigated whether visit-to-visit BPV is associated with functional decline in 
older adults at high risk of cardiovascular disease, independent of mean blood pressure, 
cardiovascular risk factors, and co-morbidities. 
 
METHODS 
Study design and participants 
The data in this study were obtained from the PROspective Study of Pravastatin in the Elderly 
at Risk (PROSPER), a randomized, double-blind, placebo-controlled trial on the effect of 
pravastatin on subsequent risk of vascular events in men and women aged 70-82 years with 
pre-existing vascular disease or risk factors thereof. We recruited 5804 participants from three 
centres in Ireland, Scotland and the Netherlands. Details of study design have been previously 
reported on13,14. Physical inability to attend clinic visits and impaired cognition at baseline 
(Mini Mental State Examination (MMSE) < 24 points) were exclusion criteria15. Blood 
  
pressure levels at baseline were no exclusion criteria. Participants were followed up for a mean 
of 3.2 years. 
From the original study population, we first excluded 820 participants with missing data on 
BPV, covariates or functional decline and subsequently excluded 239 participants in whom 
cardiovascular events (stroke, myocardial infarction and hospitalization for heart failure) 
occurred in the period of assessment of BPV, thus potentially affecting the variability. We 
included participants from both the pravastatin and the placebo arm as we previously showed 
that pravastatin did not affect functional status during follow-up14. Hence, we included 4745 
participants in the present study. The trial was approved by the Medical Ethics Committees of 
the three centres. All participants provided written informed consent. 
 
Blood pressure measurements 
We measured systolic (SBP) and diastolic (DBP) blood pressure at rest, in the sitting position, 
using a fully automatic electronic sphygmomanometer (Omron M4®). In our estimate of BPV, 
we took into account blood pressure measurements at baseline and at 3, 6, 9, 12, 15 and 18 
months. First, we calculated the intra-individual mean SBP and DBP across these 
measurements. Subsequently, we computed the intra-individual standard deviation (SD) and 
the coefficient of variation (CV; CV= intra-individual SD / intra-individual mean x 100) of 
SBP and DBP as indices of BPV. 
 
Functional status 
We assessed functional status using two questionnaires: the Barthel Index for basic Activities 
of Daily Living (ADL)16 and Lawton’s Instrumental Activities of Daily Living (IADL)17. ADL 
assesses 10 basic items: faecal continence, urinary continence, grooming, toilet use, feeding, 
transfers (for example, from chair to bed), walking, dressing, climbing stairs and bathing. IADL 
evaluates 7 more complex items: doing housework, taking medications, managing money, 
shopping, using a telephone, using technology and transportation within the community. ADL 
and IADL scores range from 0 to 20 and from 0 to 14, respectively, with higher scores 
indicating more preserved functional status. 
  
We measured functional status at 18 months, after the assessment of BPV, and subsequently at 
30, 36, 39, 42, 45 or 48 months. Functional decline in ADL and IADL was defined as the 
difference between the last measured score and the score at 18 months, divided by the time 
interval. 
 
Demographic and clinical characteristics 
At baseline, a detailed medical history was taken and blood tests performed. Education was 
defined as age at leaving school. Smoking was dichotomized as a current smoker versus a non-
current smoker. Body mass index (BMI) was calculated as weight divided by squared height 
(Kg/m2). Data on history of vascular diseases were provided by each participant’s general 
practitioner. Diabetes mellitus was defined as self-reported diagnosis, use of anti-diabetic drug 
or as fasting blood glucose of ≥ 7 mmol/L. Glomerular filtration rate (GFR), which is an index 
of kidney function, was calculated using the Modification of Diet in Renal Disease Study 
Group formula18. 
 
Statistical analysis 
We used IBM SPSS Statistics (version 20) for all analyses. Baseline characteristics of 
participants were reported as number (percentage) for categorical variables and as mean 
(standard deviation) for continuous variables. We assessed differences in baseline 
characteristics across tertiles of BPV using Pearson’s chi-squared test for categorical variables 
and ANOVA for continuous variables. 
We analysed the associations of systolic and diastolic BPV with functional status at 18 months, 
and with functional decline during follow-up, using linear regression models. All analyses were 
performed in three steps. First, we adjusted for age, sex, country of enrolment and education 
(Model 1). Second, we further adjusted for cardiovascular risk factors (smoking, BMI, 
hypertension, diabetes mellitus), cardiovascular morbidities (myocardial infarction, stroke / 
transient ischemic attack, claudication, GFR), use of antihypertensives (diuretics, angiotensin 
converting enzyme inhibitors (ACE-inhibitors), angiotensin receptor blockers, beta-blockers, 
calcium-channel blockers), statin treatment group, intra-individual mean SBP or DBP and 
  
number of measurements of SBP or DBP and, in the longitudinal associations, for ADL or 
IADL scores at 18 months (Model 2).  Finally, we additionally adjusted for baseline MMSE 
scores (Model 3). We calculated adjusted means of decline in ADL and IADL scores across 
tertiles of BPV. 
Furthermore, we repeated all analyses after stratifying the participants by 1) sex, 2) history of 
hypertension and 3) use of antihypertensives or pravastatin, in order to explore the influence 
of these parameters on the relationship between BPV and functional status. Interaction terms 
were computed by multiplying measures of BPV by these parameters. 
In addition, we performed a series of sensitivity analyses. First, we restricted the analyses to 
participants with maximum functional status at 18 months, to assess whether poor functional 
status may affect subsequent decline. Second, we restricted the analyses to participants with 
maximum MMSE score. Third, we repeated the analyses in participants who did not experience 
major incident cardiovascular events (stroke and / or myocardial infarction) during follow-up, 
to test whether the relationship between BPV and functional decline is independent of these 
incident events. 
 
RESULTS 
In the period between baseline and 18 months, the intra-individual mean SBP and DBP were 
153.7 and 83.4 mmHg and the intra-individual mean SD of SBP and DBP were 16.7 and 7.8 
mmHg, respectively. Table 1 shows the characteristics of participants in the whole study 
population and in tertiles of systolic BPV. Subjects with higher systolic BPV were older and 
more likely to be females, to have a history of hypertension, to be treated with beta-blockers 
and ACE-inhibitors at baseline, and to have lower MMSE scores and higher mean SBP (all p-
values<0.05). Similarly, subjects with higher diastolic BPV were older, more frequently had a 
history of hypertension, were on treatment with diuretics or ACE-inhibitors and had lower 
MMSE scores (all p-values<0.05, data not shown). 
Neither systolic nor diastolic BPV was associated with functional status at 18 months (data not 
shown). Figure 1 presents the longitudinal associations of systolic and diastolic BPV with 
functional decline. Higher systolic BPV was associated with a steeper decline in both ADL and 
IADL scores. After full adjustment, each 10 mmHg higher systolic BPV, as defined by SD, 
  
was associated with a 0.064 (95% confidence interval (CI) 0.016-0.112) annual decline in ADL 
score and with a 0.078 decline (95% CI 0.020-0.136) in IADL score (p-values 0.009 and 0.008, 
respectively). In contrast, diastolic BPV, as defined by SD, was not associated with functional 
decline (all p-values>0.05, for all models). Likewise, higher CV of SBP was associated with a 
steeper functional decline (all p-values<0.05), while no association was observed between CV 
of DBP and functional decline (all p-values>0.05, data not shown). 
The longitudinal associations of systolic and diastolic BPV with functional decline were not 
modified by 1) sex, 2) history of hypertension or 3) use of antihypertensives or pravastatin (all 
p-values for interaction > 0.05, Figure 2 for systolic BPV, data not shown for diastolic BPV). 
The relationship between higher systolic BPV and steeper functional decline remained 
statistically significant when restricting the analyses to participants with maximum functional 
status at 18 months (Supplementary Table 1). Likewise, it remained unchanged when 
restricting the analyses to those with maximum MMSE score (Supplementary Table 2). 
The association between higher systolic BPV and steeper functional decline tended to remain 
essentially similar in analyses restricted to participants who did not experience cardiovascular 
events during follow-up (data not shown). 
 
DISCUSSION 
In older adults at high cardiovascular risk, higher systolic BPV was associated with steeper 
functional decline, independent of intra-individual mean blood pressure, cardiovascular risk 
factors and morbidities, cognition and use of antihypertensives. 
Consistent with earlier reports, we found that higher BPV was associated with older age, female 
sex, use of ACE-inhibitors, and poor cognition19,20. Our novel finding is the association 
between systolic BPV and functional decline, independent of cognition. The lack of association 
between diastolic BPV and clinical outcomes in our study is in line with previous research, 
showing no association of diastolic BPV with subclinical brain damage, cognition and 
mortality19, 21-24. This may result from a lower magnitude of diastolic compared to systolic 
BPV. 
  
Different interpretations may explain our findings. First, both higher BPV and functional 
decline may share common causes such as atherosclerosis. Atherosclerosis may lead to higher 
BPV through increased arterial stiffness and reduced damping of blood pressure wave within 
vessels10. Moreover, the link between atherosclerosis and functional decline is well 
established11,12. However, adjustment for history of cardiovascular morbidities, which can be 
seen as a marker of atherosclerotic burden, did not change our findings. Another shared cause 
may be neurodegenerative diseases. Neurodegenerative diseases, including Alzheimer’s, have 
been linked to central autonomic dysregulation, in particular impaired baroreflex function25. 
Impaired baroreflex function could explain higher BPV and is present in the early stages of 
Alzheimer’s, when cognition is quite preserved25. Furthermore, it is debated whether 
neurodegenerative diseases may be linked to unbalanced blood pressure regulation via 
impaired parasympathetic cholinergic neurotransmission25-27. However, our results remained 
unchanged after adjusting for cognition and after restricting the analyses to participants with 
maximum MMSE score. 
Alternatively, higher BPV may contribute to functional decline by causing oscillations in 
cerebral perfusion28. Inadequate cerebral perfusion could lead to neuronal injury and 
degeneration29. Indeed, hypotension has been linked to lesions in brain frontal-subcortical 
circuits involved in motor and bladder control30. Cerebral white matter is particularly 
vulnerable to abrupt drops in blood pressure and transient ischemia31. Of note, higher systolic 
but not diastolic BPV has been linked to cerebral white matter lesions, which, in turn, have 
been associated with gait and balance instability, falls, executive dysfunction and depression 
in older adults22-24,32,33. Furthermore, recent studies suggest that inadequate cerebral perfusion 
may reduce the paravascular clearance of amyloid-β42 from the brain, thus favouring the 
development of neurodegenerative diseases34,35. 
Higher BPV may be linked to functional decline through incident major cardiovascular events. 
A trend of association between higher systolic BPV and steeper functional decline was 
observed also in participants who did not experience incident major vascular events, thus 
suggesting that subclinical vascular damage may also play a role. In particular, higher BPV can 
potentially lead to subclinical damage of crucial organs such as the heart and the kidneys, by 
inducing frequent episodes of hypo- and hypertension. In turn, subclinical cardiac and kidney 
damage may lead to functional decline in older adults. 
  
Observational studies have provided evidence for the association of higher BPV with 
subclinical cardiac and kidney damage. A correlation between higher BPV and subclinical left 
ventricular diastolic dysfunction, but not hypertrophy, has been found36,37; in turn, left 
ventricular diastolic dysfunction predicts reduced likelihood of independent living in older 
adults38. Furthermore, higher BPV has been longitudinally associated with deterioration of 
kidney function39-41. Diminished kidney function, even within the normal range, has been 
associated with muscle atrophy, reduced walking speed, and steeper decline in lower-extremity 
strength in older adults42. Nonetheless, evidence from observational studies cannot prove a 
causal relationship between BPV and subclinical cardiac and kidney damage. 
In our study, the association between systolic BPV and functional decline did not differ 
between hypertensive and non-hypertensive individuals. This finding may highlight the 
significance of current BPV, independently of previous history of hypertension. 
The major strength of our study is the longitudinal design, showing that higher blood pressure 
variability precedes the decline in functional status. Further strengths are the large sample size, 
the lack of restriction on blood pressure at baseline, the consistency of our findings using two 
different indexes of BPV (SD and CV) and the adjustment for several potential confounders. 
Our participants were older adults at high cardiovascular risk, generally with high functional 
status. Therefore, our findings may not be generalizable to populations with different age, risk 
profile or functional status. However, our study population combines a high risk for functional 
decline together with a high potential for benefit from interventions aimed at preventing or 
delaying it. 
In conclusion, higher visit-to-visit systolic BPV was longitudinally associated with steeper 
functional decline in older adults at high cardiovascular risk. We suggest that higher systolic 
BPV is a risk factor for functional decline and should be included in the clinical assessment of 
older adults at high cardiovascular risk. Further research should explore whether interventions 
aimed at reducing systolic BPV may preserve functional status. 
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Table 1. Characteristics of study population in tertiles of systolic blood pressure 
variability 
 Whole 
cohort 
Tertiles of SD of SBP (mmHg)  
Characteristics  
n=4745 
Low 
(1.73-11.21) 
n=1581 
Middle 
(11.22-15.63) 
n=1582 
High 
(15.64-42.71) 
n=1582 
p-value 
Socio-demographics      
Age, years, mean (SD) 75.2 (3.3) 74.8 (3.3) 75.2 (3.3) 75.6 (3.4) <0.001 
Female, n (%) 2494 (52.6) 797 (50.4) 824 (52.1) 873 (55.2) 0.024 
Age left school, years, mean (SD) 15.2 (2.1) 15.2 (2.1) 15.1 (2.1) 15.2 (2.0) 0.152 
Vascular risk factors / 
morbidities 
     
Hypertension, n (%) 2970 (62.6) 920 (58.2) 985 (62.3) 1065 (67.3) <0.001 
Stroke or TIA, n (%) 515 (10.9) 161 (10.2) 162 (10.2) 192 (12.1) 0.133 
Myocardial infarction, n (%) 593 (12.5) 215 (13.6) 192 (12.1) 186 (11.8) 0.255 
Claudication, n (%) 282 (5.9) 86 (5.4) 90 (5.7) 106 (6.7) 0.283 
Diabetes mellitus, n (%) 483 (10.2) 160 (10.1) 168 (10.6) 155 (9.8) 0.743 
Current smoking, n (%) 1212 (25.5) 433 (27.4) 396 (25.0) 383 (24.2) 0.104 
BMI, kg/m 2 , mean (SD) 26.9 (4.2) 26.9 (4.2) 26.8 (4.2) 26.9 (4.1) 0.947 
GFR, mL/min, mean (SD) 60.2 (14.3) 60.3 (13.6) 60.7 (14.4) 59.7 (14.8) 0.115 
Antihypertensive drugs      
Beta-blockers, n (%) 1238 (26.1) 350 (22.1) 418 (26.4) 470 (29.7) <0.001 
Diuretics, n (%) 1909 (40.2) 629 (39.8) 634 (40.1) 646 (40.8) 0.824 
ACE-inhibitors, n (%) 765 (16.1) 184 (11.6) 255 (16.1) 326 (20.6) <0.001 
Angiotensin-antagonists, n (%) 93 (2.0) 29 (1.8) 31 (2.0) 33 (2.1) 0.878 
Calcium-channel blockers, n (%) 1175 (24.8) 410 (25.9) 374 (23.6) 391 (24.7) 0.328 
Treatment group      
Pravastatin, n (%) 2370 (49.9) 810 (51.2) 794 (50.2) 766 (48.4) 0.278 
Cognition      
MMSE, score, mean (SD) 28.1 (1.5) 28.2 (1.5) 28.1 (1.5) 28.0 (1.5) 0.022 
Blood pressure (0-18 months)      
Average SBP, mmHg, mean (SD) 153.7 (16.7) 150.3 (16.4) 153.3 (16.3) 157.5 (16.7) <0.001 
N of measurements, mean (SD) 6.9 (0.5) 6.9 (0.6) 6.9 (0.4) 6.9 (0.5) 0.321 
Abbreviations: SD: Standard Deviation, SBP: systolic blood pressure, n: number, TIA: Transient Ischemic Attack, 
BMI: Body Mass Index, GFR: glomerular filtration rate. P-values were computed using Pearson’s chi-square test 
or Kruskal-Wallis test as appropriate. 
  
Figure 1. Decline in ADL and IADL scores in relation to systolic and diastolic blood 
pressure variability 
 
Bars represent means and standard error. β are beta-coefficients (95% confidence intervals) for annual change in 
ADL/IADL score for each 10 mmHg increase in blood pressure variability. P-values were calculated using 
continuous measures of systolic and diastolic blood pressure variability. Abbreviations: BPV: blood pressure 
variability, ADL: activities of daily living, IADL: instrumental activities of daily living. Analyses were adjusted 
for country, age, sex, education, smoking, body mass index, history of hypertension, history of diabetes mellitus, 
history of claudication, history of myocardial infarction, history of stroke/transient ischemic attack, glomerular 
filtration rate, statin treatment, diuretics, Angiotensin Converting Enzyme inhibitors, angiotensin receptor 
blockers, beta-blockers, calcium-channel blockers, ADL/IADL at 18 months, mean systolic blood pressure, 
number of measurements of systolic blood pressure and baseline Mini Mental State Examination score.  
 
  
Figure 2. Decline in ADL and IADL scores in relation to systolic blood pressure 
variability by sex, history of hypertension, use of antihypertensives or statin 
 
Bars represent means and 95% confidence interval. Analyses were adjusted for country, age, sex, education, 
smoking, body mass index, history of hypertension, history of diabetes mellitus, history of claudication, history 
of myocardial infarction, history of stroke/transient ischemic attack, glomerular filtration rate, statin treatment, 
diuretics, Angiotensin Converting Enzyme inhibitors, angiotensin receptor blockers, beta-blockers, calcium-
channel blockers, ADL/IADL score at 18 months, mean systolic blood pressure, number of measurements of 
systolic blood pressure and baseline Mini Mental State Examination score. Abbreviations: n: number, ADL: 
activities of daily living, IADL: instrumental activities of daily living, Ca-C: calcium-channel, ACE: Angiotensin 
Converting Enzyme inhibitors, AA: angiotensin receptor blockers. 
  
  
Supplementary Table 1. Decline in ADL and IADL scores in relation to systolic and 
diastolic BPV in participants with maximum ADL/IADL score at 18 months 
 Annual change in functional status per 10 
mmHg increase in BPV [95% CI] 
p-value 
Systolic BPV   
 ADL (score/year, n=4069)   
   Model 1 -0.084 [-0.127; -0.042] <0.001 
   Model 2 -0.085 [-0.129; -0.041] <0.001 
   Model 3 -0.083 [-0.127; -0.039] <0.001 
 IADL (score/year, n=3776)   
   Model 1 -0.121 [-0.179; -0.062] <0.001 
   Model 2 -0.116 [-0.176; -0.056] <0.001 
   Model 3 -0.111 [-0.170; -0.051] <0.001 
Diastolic BPV 
  
ADL (score/year, n=4069)   
   Model 1 -0.060 [-0.139; 0.020] 0.140 
   Model 2 -0.057 [-0.137; 0.022] 0.159 
   Model 3 -0.053 [-0.133; 0.027] 0.192 
 IADL (score/year, n=3776)   
   Model 1 -0.064 [-0.171; 0.042] 0.237 
   Model 2 -0.053 [-0.161; 0.054] 0.332 
   Model 3 -0.040 [-0.147; 0.067] 0.465 
Annual change is calculated as the difference between the last ADL/IADL score and ADL/IADL score at 18 
months divided by time interval. BPV was defined as standard deviation of systolic/diastolic blood pressure across 
visits. Abbreviations: BPV: blood pressure variability; ADL: Activities of Daily Living; IADL: Instrumental 
Activities of Daily Living. Model 1: adjusted for country, age, sex, education. Model 2: adjusted for country, age, 
sex, education, smoking, body mass index, history of hypertension, history of diabetes mellitus, history of 
claudication, history of myocardial infarction, history of stroke/transient ischemic attack, glomerular filtration 
rate, statin treatment, diuretics, Angiotensin Converting Enzyme inhibitors, angiotensin receptor blockers, beta-
blockers, calcium-channel blockers, ADL/IADL at 18 months, mean systolic/diastolic blood pressure and number 
of measurements of systolic/diastolic blood pressure. Model 3: model 2 is additionally adjusted for baseline Mini 
Mental State Examination score. 
  
Supplementary Table 2. Decline in ADL and IADL scores in relation to systolic and 
diastolic blood pressure variability in participants with maximum MMSE score 
 Annual change in functional status per 10 
mmHg increase in BPV [95% CI] 
p-value 
Systolic BPV   
 ADL (score/year, n=881)   
   Model 1 -0.105 [-0.182; -0.027] 0.008 
   Model 2 -0.088 [-0.168; -0.007] 0.032 
 IADL (score/year, n=881)   
   Model 1 -0.132 [-0.229; -0.035] 0.008 
   Model 2 -0.120 [-0.221; -0.019] 0.020 
Diastolic BPV 
  
ADL (score/year, n=881)   
   Model 1 -0.045 [-0.186; 0.096] 0.527 
   Model 2 -0.028 [-0.168; 0.112] 0.697 
 IADL (score/year, n=881)   
   Model 1 -0.070 [-0.247; 0.106] 0.435 
   Model 2 -0.052 [-0.228; 0.125] 0.565 
Annual change is calculated as the difference between the last ADL/IADL score and ADL/IADL score at 18 
months divided by time interval. BPV was defined as standard deviation of systolic/diastolic blood pressure across 
visits. Abbreviations: BPV: blood pressure variability; ADL: Activities of Daily Living; IADL: Instrumental 
Activities of Daily Living, MMSE: Mini Mental State Examination score. Model 1: adjusted for country, age, sex, 
education. Model 2: adjusted for country, age, sex, education, smoking, body mass index, history of hypertension, 
history of diabetes mellitus, history of claudication, history of myocardial infarction, history of stroke/transient 
ischemic attack, glomerular filtration rate, statin treatment, diuretics, Angiotensin Converting Enzyme inhibitors, 
angiotensin receptor blockers, beta-blockers, calcium-channel blockers, ADL/IADL at 18 months, mean 
systolic/diastolic blood pressure and number of measurements of systolic/diastolic blood pressure.  
  
 
 
 
 
 
 
 
 
 
Chapter 7 
General discussion 
 
  
  
General discussion 
Key findings 
This thesis aimed to explore the determinants of healthy ageing and longevity in older 
populations, with particular focus on the homeostasis of the cardiovascular system. This thesis 
examined both a cohort of geriatric outpatients, a population in whom homeostasis may be 
affected by a complex interplay with comorbidities and frailty, and a trial cohort of old adults 
with preserved functional status but high cardiovascular risk, in whom the early stages of 
functional decline could be depicted. 
In geriatric outpatients, we showed that the relationship between blood pressure and health 
outcomes was modified by chronological and biological age as defined by functional and 
cognitive status. In particular, higher blood pressure was associated with better cognitive 
function in those outpatients aged 85 years and older and in those with impaired functional 
status. Moreover, higher systolic blood pressure (below 180 mmHg) was associated with 
decreased all-cause mortality risk in outpatients with impaired functional and cognitive status, 
but not in those with preserved functional and/or cognitive status. In the same cohort, we 
reported that optimal thyroid status differed by sex, possibly as a consequence of higher 
cardiovascular burden in men compared to women. Among euthyroid older outpatients, low 
normal thyroid status, as characterised by high TSH and low fT4, was associated with 
decreased mortality risk in men whereas not in women. 
In the PROSPER cohort, we examined the cross-sectional and longitudinal associations 
between markers of cardiac autonomic function and functional status. Cardiac autonomic 
function has been consistently associated with cardiovascular risk factors and comorbidities, 
which in turn have been related to functional decline1-6. Here, we showed the direct link 
between cardiac autonomic function and functional decline, independent of cardiovascular risk 
factors and comorbidities. Even among adults with preserved functional status, higher heart 
rate, lower heart rate variability and higher blood pressure variability could identify those at a 
higher risk of future functional decline. 
 
 
  
Generalizability of findings 
In our geriatric outpatients, chronological and biological age, as defined by impairments in 
functional and cognitive status, modulated the relationship between blood pressure and health 
outcomes. In the oldest and in the frailest adults, higher blood pressure was associated with 
better cognition and decreased mortality risk. Our findings are in line with those from 
population-based studies, whereas they conflict with those from clinical trials7-14. Looking into 
the demographic and clinical characteristic of our study population, we could hypothesize a 
continuum of frailty that places older adults of clinical trials among the fittest, those of 
population-based studies in an intermediate position and those of the Milan Geriatrics 75+ 
Cohort Study among the frailest (Figure 1). This hypothesis may explain why our findings are 
closer to those of population-based studies rather than those from clinical trials. It further 
highlights that findings from trials may not be applicable to everyday clinical practice due to 
the higher complexity of patient populations. Therefore, it is of high clinical relevance to 
perform research in patient populations. 
 
Figure 1. Continuum fitness-frailty in different types of epidemiologic studies 
 
 
 
  
Clinical implications: towards tailored treatment in old age 
This thesis adds to previous literature showing that the homeostasis of frail older adults may 
differ from that of younger or fitter adults. In particular, our findings may indicate that optimal 
blood pressure targets may shift towards higher values with advancing age and frailty, possibly 
to guarantee adequate perfusion of vital organs15-17. Therefore, we advocate that blood pressure 
management in old age should be tailored taking into account both chronological and biological 
age. Although a consensus definition of biological age or frailty is lacking18, by defining it 
according to functional and cognitive status, we were able to effectively distinguish 
subpopulations of older adults in whom blood pressure goals may differ. 
Furthermore, we showed that optimal thyroid status may vary according to sex and age, with 
high normal TSH being associated with reduced mortality risk in the oldest men. In middle-
age, high normal TSH may be indicative of occult thyroid disease, which has been linked to 
increased morbidity and mortality19. Conversely, high normal TSH in old age may be a 
heritable trait linked to longevity, as it has been has been found in exceptionally long-lived 
adults and their offspring20-21. Therefore, in line with previous research, we advocate that TSH 
reference limits should be age- and sex-specific22. In particular, we advocate that TSH upper 
normal reference limit should be higher in older compared to younger men. 
 
Novel cardiovascular risk factors for functional decline 
This thesis’ novel finding is that heart rate, heart rate variability and blood pressure variability, 
markers of cardiovascular homeostasis, are associated with risk of future functional decline, 
independent of comorbidities. Suboptimal cardiovascular homeostasis may be linked to 
functional decline through reduced resilience to stressors. While previous research focussed on 
specific cardiovascular diseases as outcomes, our outcome was functional decline, a global 
measure of disability of high relevance for individuals and society. As functional decline may 
considerably differ among individuals with the same diseases, it is worth shifting the focus on 
functional decline itself and gain insight into the mechanisms underlying it, independent of 
diseases. 
 
  
Future perspectives 
This thesis explored a complex and heterogeneous outpatient population, highlighting its 
diversity from those of clinical trials and population-based studies, and suggesting that 
associations between cardiovascular parameters and health outcomes may be reversed by age 
and frailty. Frailer older adults are generally excluded or less likely to be included in clinical 
trials and population-based studies, whereas they are referred to geriatric outpatient practices. 
The geriatric outpatients of the Milan Geriatrics 75+ Cohort Study comprised both the fitter 
and the frailer older adults. In this population, cognitive status ranged from preserved to 
severely impaired, functional status from complete independence to complete dependence, 
comorbidities from absent to numerous, and medications from none to polypharmacy. This 
heterogeneity represents a limit when not taken into account, whereas a strength when stratified 
analyses are performed. Our stratified analyses allowed us to show that the relationship 
between blood pressure and health outcomes may be reversed by impaired functional and 
cognitive status. 
It is crucial to further investigate this outpatient population, as it is representative of patients 
for whom clinicians have to make treatment decisions in everyday practice. 
This thesis reports also on findings from more classic observational studies, here based on a 
trial cohort. This cohort is skewed towards better health as frail individuals were by design not 
enrolled. Because of this selection, and given the observational design, we cannot infer whether 
our reported associations are causal. Further research is needed to establish whether 
cardiovascular parameters and thyroid status are merely risk markers or potentially modifiable 
risk factors for adverse health outcomes. Identifying modifiable risk factors is the first step 
towards intervention to delay functional and cognitive decline and mortality. Any intervention 
should be tested in the context of randomized controlled trials. However, trials may be long, 
costly or unfeasible due to ethical considerations in vulnerable older populations. 
Most trials selectively include older adults with few comorbidities and no dementia; indeed, a 
recent community-based study found that only 9% of the oldest adults with hypertension were 
eligible for inclusion in The Hypertension in the Very Elderly Trial23,24. Recently, the 
randomised controlled trial Discontinuation of Antihypertensive Treatment in Elderly People 
(DANTE) Study Leiden investigated the effects of withdrawing antihypertensive treatment on 
cognition in older adults with mild cognitive impairment, showing no effect at the 16-week 
  
follow-up25. The generalizability and the power of this trial were limited by the strict inclusion 
criteria (only old adults without serious cardiovascular diseases were included) and by the short 
duration of follow-up due to safety reasons. Thus, the DANTE Study Leiden illustrates the 
constraints encountered by researchers when dealing with older populations. 
Nonetheless, we advocate that future trials may be performed in older populations in hospital-
based outpatients setting, thus combining the evidence on the intervention with the high 
generalizability to clinical practice. These hospital-based trials may investigate the safety and 
efficacy of either introducing or withdrawing medications. Moreover, they may test non-
pharmacological treatments such as diet and physical exercise. Choosing functional and 
cognitive decline as outcomes may favour both the comprehension and the willingness to 
participate of patients and caregivers. Including both the frailer and the fitter older adults may 
favour insight on how the benefits and harms of intervention may be modified by frailty. The 
threshold of frailty at which the harms may equal or outweigh the benefits should be assessed. 
At present, given the limits of trials, valuable evidence may be derived from observational 
studies, coupled with deeper understanding of the pathophysiological mechanisms underlying 
homeostasis and homeostasis loss. 
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Chapter 8 
Summary in English 
 
  
  
Summary in English 
Chapter 1 provides a background on the demography of population ageing in Europe and Italy 
and the consequent emergence of age-related diseases as causes of disability and mortality. It 
illustrates how preserving homeostasis is crucial to delay functional and cognitive decline as 
well as mortality, and suggests that homeostasis may vary in old compared to young age. 
Furthermore, it highlights the controversies in scientific literature regarding optimal blood 
pressure and thyroid status in old age and the pitfalls of evidence derived from clinical trials 
and population-based studies. Finally, it introduces the Milan Geriatrics 75+ Cohort Study, 
which was conceived to provide novel evidence on older outpatients’ populations, whom 
clinicians encounter in everyday clinical practice. It also describes PROSPER, a randomized 
controlled trial on statin use in a population of old adults at high cardiovascular risk, the second 
cohort on which the research work for this thesis has been done. 
Chapter 2 presents findings on the association between blood pressure and cognition in the 
Milan Geriatrics 75+ Cohort Study, indicating that higher blood pressure was associated with 
better cognition especially in the oldest old and in those with impaired functional status. Both 
chronological age and biological age as defined as impaired functional status significantly 
modified the relationship between blood pressure and cognition. 
In Chapter 3, we investigated the relationship between blood pressure and mortality risk in 
the Milan Geriatrics 75+ Cohort Study. We showed that the relationships of systolic and 
diastolic blood pressure with mortality risk were U-shaped; systolic blood pressure of 165 
mmHg and diastolic blood pressure of 85 mmHg were associated with the lowest mortality 
risk. When focussing on older adults with systolic blood pressure below 180 mmHg, higher 
systolic blood pressure was associated with lower mortality risk in older adults with impaired 
functional and cognitive status but not in those with preserved functional and/or cognitive 
status. 
Chapter 4 explores the association between thyroid status and mortality risk in a sample of 
euthyroid older adults of the Milan Geriatrics 75+ Cohort Study. It shows that higher TSH and 
lower fT4 were associated with decreased mortality risk in men, but not in women. Sex 
significantly modified the relationships of TSH and fT4 with mortality risk. In addition, the 
inverse relationship between TSH and mortality risk was most pronounced in men aged 85 
years and over. 
  
Chapter 5 presents novel findings on the association between resting heart rate, heart rate 
variability and functional decline in older adults at high cardiovascular risk. Higher resting 
heart rate and lower heart rate variability were associated with worse functional status and with 
higher risk of future functional decline. It also explores the pathophysiological mechanisms 
that may link these markers of cardiac autonomic function to functional decline. 
Chapter 6 examines the relationship between visit-to-visit blood pressure variability and 
functional decline in older adults at high cardiovascular risk. It expands our current knowledge 
on the associations between blood pressure variability and adverse health outcomes, by 
showing that higher systolic blood pressure variability was associated with steeper functional 
decline. This association was independent of mean blood pressure, cardiovascular risk factors 
and comorbidities and cognition. 
Chapter 7 summarises the key findings of this thesis, highlighting their novelty in the context 
of scientific literature. It was concluded that there is a need for hospital-based cohorts in which 
to explore whether the relationships between risk factors and health outcomes may vary across 
the wide spectrum of biological and chronological age. Moreover, findings from these cohorts 
should guide appropriate clinical trials that are needed to assess the benefits and harms of either 
introducing or withdrawing medications in older adults. 
  
  
 
 
 
 
 
 
 
 
 
Chapter 9 
Summary in Italian 
 
  
  
Riassunto in italiano 
Il Capitolo 1 fornisce una panoramica sugli aspetti demografici dell’invecchiamento della 
popolazione in Europa e in Italia e sul consequente emergere delle patologie età-correlate quali 
cause di disabilità e mortalità. Illustra come preservare l’omeostasi sia cruciale al fine di 
posporre sia il declino funzionale e cognitivo sia la mortalità, e suggerisce come l’omeostasi 
possa variare nell’età avanzata rispetto all’età giovanile. Inoltre, evidenzia le controversie 
esistenti nella letteratura scientifica riguardo ai valori ottimali di pressione arteriosa e 
funzionalità tiroidea nell’età avanzata e le problematiche nell’estrapolare l’evidenza ottenuta 
da trial clinici e studi di popolazione. Infine, introduce lo studio Milan Geriatrics 75+ Cohort 
Study, che fu disegnato al fine di fornire nuova evidenza su popolazioni di pazienti anziani 
ambulatoriali, che i clinici incontrano nella pratica clinica quotidiana. Il Capitolo 1 descrive 
inoltre lo studio PROSPER, un trial randomizzato controllato sull’uso di statina in una 
popolazione di anziani ad alto rischio cardiovascolare, la seconda coorte in cui il lavoro di 
ricerca per questa tesi è stato svolto. 
Il Capitolo 2 presenta i risultati sulla associazione tra pressione arteriosa e cognizione nello 
studio Milan Geriatrics 75+ Cohort Study, che mostrano come maggiori valori di pressione 
arteriosa siano associati a migliori performance cognitive soprattutto nei grandi anziani ‘’oldest 
old’’ e negli anziani con compromissione dello stato funzionale. Sia l’età cronologica sia l’età 
biologica, definita quale compromissione dello stato funzionale, modificarono 
significativamente la relazione tra pressione arteriosa e stato cognitivo. 
Nel Capitolo 3, abbiamo investigato la relazione tra pressione arteriosa e rischio di mortalità 
nello studio Milan Geriatrics 75+ Cohort Study. Abbiamo dimostrato che le associazioni di 
pressione arteriosa sistolica e diastolica con il rischio di mortalità avevano un andamento ad U; 
la pressione arteriosa sistolica di 165 mmHg e la pressione arteriosa diastolica di 85 mmHg 
erano associate con il minore rischio di mortalità. Quando ci siamo soffermati sugli anziani con 
pressione arteriosa sistolica inferiore a 180 mmHg, maggiori valori di pressione arteriosa 
sistolica erano associati a minor rischio di mortalità negli anziani con compromesso stato 
funzionale e cognitivo ma non in quelli con preservato stato funzionale e/o cognitivo. 
Il Capitolo 4 esplora l’associazione tra funzionalità tiroidea e rischio di mortalità in un 
campione di anziani eutiroidei dello studio Milan Geriatrics 75+ Cohort Study. Dimostra che 
maggiori valori di TSH e minori valori di fT4 erano associati ad un minore rischio di mortalità 
  
negli uomini, ma non nelle donne. Il sesso significativamente modificava le associazioni di 
TSH e fT4 con il rischio di mortalità. Inoltre, l’associazione inversa tra TSH e rischio di 
mortalità era più accentuata negli uomini di età pari o superiore a 85 anni. 
Il Capitolo 5 presenta nuovi riscontri sull’associazione di frequenza cardiaca e variabilità nella 
frequenza cardiaca a riposo con il declino funzionale in anziani ad alto rischio cardiovascolare. 
Maggiori valori di frequenza cardiaca a riposo e minori valori di variabilità nella frequenza 
cardiaca a riposo erano associati ad un peggiore stato funzionale e ad un maggiore rischio di 
futuro declino funzionale. Il Capitolo 5 inoltre esplora i meccanismi patofisiologici che 
possono legare tali marcatori della funzione autonomica cardiaca al declino funzionale. 
Il Capitolo 6 esamina l’associazione tra variabilità della pressione arteriosa, da visita a visita, 
con il declino funzionale in anziani ad alto rischio cardiovascolare. Il Capitolo 6 espande la 
nostra attuale conoscenza sulle associazioni tra variabilità della pressione arteriosa e eventi 
avversi alla salute, dimostrando che una maggiore variabilità della pressione arteriosa sistolica 
era associata ad un più rapido declino funzionale. Tale associazione era indipendente dai valori 
medi di pressione arteriosa, dai fattori di rischio cardiovascolare, dalle comorbidità 
cardiovascolari e dallo stato cognitivo. 
Il Capitolo 7 riassume i risultati principali di tale tesi, sottolineando la loro originalità nel 
contesto della letteratura scientifica. Si conclude che vi è la necessità di coorti basate negli 
ospedali in cui esplorare se le associazioni tra fattori di rischio e obiettivi di salute possa variare 
nell’ampio spettro dell’età biologica e cronologica. Inoltre, i riscontri osservati in tali coorti 
devono guidare appropriati trial clinici che sono necessari al fine di stabilire i benefici e i danni 
dell’introduzione o della sospensione di terapie farmacologiche negli anziani. 
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Nederlandse samenvatting 
Hoofdstuk 1 introduceert de demografie van de veroudering in Europa en Italië en de daaruit 
voortvloeiende opkomst van aan leeftijd gerelateerde ziekten als oorzaken van functionele 
beperkingen en mortaliteit. Het illustreert hoe het behoud van homeostase cruciaal is om het 
optreden van zowel cognitieve en functionele achteruitgang als mortaliteit uit te stellen, en stelt 
dat de homeostase op oudere en jongere leeftijd uiteen kan lopen. Bovendien wordt gewezen 
op de tegenstrijdige literatuur wat betreft optimale bloeddruk en schildklierfunctie op oudere 
leeftijd, en de tekortkomingen van wetenschappelijk bewijs verkregen uit klinische trials en 
bevolkingsonderzoek. Ten slotte wordt de Milan Geriatrics 75+ Cohort Study geïntroduceerd, 
die werd uitgevoerd om nieuw inzichten te verwerven over poliklinische populaties van oudere 
patiënten, waar clinici dagelijks mee te maken krijgen. Tevens wordt PROSPER beschreven, 
een gerandomiseerd placebo-gecontroleerd onderzoek naar statinegebruik bij oudere 
individuen met een hoog cardiovasculair risico, het tweede cohort waarop het onderzoek 
beschreven in dit proefschrift is gebaseerd.  
Hoofdstuk 2 presenteert de bevindingen over het verband tussen bloeddruk en cognitie uit de 
Milan Geriatrics 75+ Cohort Study. Een hogere bloeddruk was geassocieerd met betere 
cognitie, met name bij de oudste ouderen en bij diegenen met een verminderde functionele 
status. Zowel chronologische leeftijd als biologische leeftijd, gedefinieerd als een verminderde 
functionele status, modificeerde de relatie tussen bloeddruk en cognitie. 
Hoofdstuk 3 toont ons onderzoek naar de relatie tussen bloeddruk en sterfterisico in de Milan 
Geriatrics 75+ Cohort Study. Wij lieten zien dat de relatie tussen bloeddruk en sterfterisico U-
vormig is. Hierbij waren een systolische bloeddruk van 165 mmHg en een diastolische 
bloeddruk van 85 mmHg geassocieerd met het laagste sterfterisico. Bij ouderen met een 
systolische bloeddruk onder de 180 mmHg was een hogere systolische bloeddruk geassocieerd 
met een lager risico op sterfte bij diegenen met een verminderde functionele en cognitieve 
status, echter niet bij diegenen met een behouden functionele en/of cognitieve status. 
Hoofdstuk 4 beschrijft de onderzochte relatie tussen schildklierfunctie en het sterfterisico in 
de euthyroïde deelnemers van de Milan Geriatrics 75+ Cohort Study. Het toont hoe zowel 
hogere TSH als lagere fT4 geassocieerd waren met een lagere kans op overlijden bij mannen, 
  
maar niet bij vrouwen. Geslacht modificeerde de associatie van TSH en fT4 met sterfterisico. 
Bovendien was de omgekeerde relatie tussen TSH en sterfterisico het meest uitgesproken bij 
mannen van 85 jaar en ouder. 
Hoofdstuk 5 presenteert nieuwe inzichten in het verband tussen de hartslag in rust, 
hartslagvariabiliteit en functionele achteruitgang bij oudere volwassenen met een hoog 
cardiovasculair risico. Hogere hartslag in rust en lagere hartslagvariabiliteit waren geassocieerd 
met zowel slechtere functionele status als met een hoger risico op functionele achteruitgang in 
de toekomst. Tevens werden de pathofysiologische mechanismen onderzocht die deze markers 
van cardiale autonome functie kunnen koppelen aan functionele achteruitgang. 
Hoofdstuk 6 gaat in op de relatie tussen de ‘bezoek-tot-bezoek’ bloeddrukvariabiliteit en 
functionele achteruitgang bij oudere volwassenen met een hoog cardiovasculair risico. Het 
breidt onze huidige kennis over de relatie tussen bloeddrukvariabiliteit en negatieve 
gezondheidseffecten uit, door te laten zien dat een hogere systolische bloeddrukvariabiliteit 
associeert met snellere functionele achteruitgang. Deze bevinding was onafhankelijk van de 
gemiddelde bloeddruk, cardiovasculaire risicofactoren, cardiovasculaire co-morbiditeit en 
cognitie. 
Hoofdstuk 7 geeft een overzicht van de belangrijkste bevindingen van dit proefschrift en 
benadrukt de nieuw verworven inzichten voor de wetenschappelijke literatuur. Er werd 
geconcludeerd dat ziekenhuis-gebaseerde cohorten nodig zijn om te onderzoeken of de 
samenhang tussen risicofactoren en gezondheidseffecten varieert over het brede spectrum aan 
biologische en chronologische leeftijd. Bovendien dienen de bevindingen van deze cohorten 
leidend te zijn voor klinische trials, welke noodzakelijk zijn om de voor- en nadelen van zowel 
het starten als stoppen van medicatie bij oudere volwassenen te evalueren. 
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